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Chapter 1
Scope of the Thesis
2Chapter 1
Cholestatic and steatotic liver diseases comprise a significant share of the total burden of 
chronic liver diseases. Both cholestatic (e.g., primary biliary cirrhosis: PBC, and primary sclerosing 
cholangitis: PSC) and steatotic (e.g., non-alcoholic steatohepatitis: NASH) liver diseases are 
associated with a high morbidity and mortality. Existing therapeutic agents are either not very 
effective (e.g., steroids or UDCA for PBC) or are associated with severe difficulties (e.g., liver 
transplantation: donor organ shortage, organ rejection, etc). 
One of the reasons for the lack of effective treatment for cholestatic and steatotic liver diseases 
is the lack of detailed knowledge about the pathogenetic mechanisms of these diseases. Both groups 
of diseases are characterized by a gradual and progressive loss of viable hepatocytes leading to liver 
inflammation, fibrogenesis and end-stage liver disease. Cell loss can occur via either apoptosis or 
necrosis (or intermediate forms). However, extensive controversy exists about these basic knowledge 
such as the dominant mode of cell death in these disorders. In addition, any intervention or 
therapeutic strategy should be effective in “diseased” (i.e. steatotic or cholestatic) hepatocytes, since 
patients with chronic liver diseases usually visit clinicians when their disease is already advanced. 
The aim of this thesis is to elucidate the mechanisms of cell death in (diseased) hepatocytes, in order 
to develop strategies to protect (diseased) hepatocytes and prevent liver injury. 
In chapter 2, the current knowledge on hepatocyte cell death with special emphasis on 
intracellular organelle-mediated cell death and membrane-bound receptors regulating apoptosis, 
is reviewed. In chapter 3, the dominant mode of cell death in steatotic hepatocytes in an in vivo 
model of non-alcoholic fatty liver disease (NAFLD) is investigated and it is related to alterations in 
mitochondrial-mediated signaling pathways.
Angiotensin receptor blockers (ARBs) are suggested as new therapeutics for the treatment of 
liver fibrosis. In chapter 4, the effects of angiotensin II (AT-II) versus ARBs on hepatocytes exposed 
to bile salts, reactive oxygen species and cytokines are investigated. 
Chapter 5 describes the protective effect of pertussis toxin, the Gαi-protein inhibitor, on 
bile salt- and cytokine-induced apoptotic cell death. This chapter emphasizes the involvement 
of G-protein coupled receptors (GPCR) in hepatocyte apoptosis and suggests new targets for 
therapeutic intervention.
Understanding bile salt-induced signaling pathways is crucial for the developmentof novel drugs 
for cholestatic disorders. Chapter 6 reports a novel bile salt-induced signaling pathway involving 
sphingosine kinase-1(SphK1), sphingosine-1 phosphate (S1P, an intracellular lipid molecule 
potentially acting as a second messenger) and S1P receptors in primary hepatocytes.
Chapter 2
General Introduction
Hepatocyte apoptosis: interplay of intracellular organelles and
 membrane-bound receptors
4Chapter 2
Liver diseases belong to the top 10 of leading diseases for humans. In clinical practice, liver 
injury is divided into acute and chronic diseases, based on the duration or persistence of liver 
injury. After recovery from acute liver injuries, normal liver function and architecture are restored. 
In contrast, in most chronic liver injuries liver functions are abnormal and persistent changes in 
liver architecture occur. Hepatocytes comprise 80% of all liver cells and hepatocyte injury is often 
central in the pathogenesis of liver diseases [1]. Prolonged hepatocyte injury results in an excessive 
wound healing response, leading to hepatic inflammation and fibrogenesis. Liver fibrosis is the 
hall mark of chronic liver diseases that may progress to end-stage liver disease and hepatocellular 
carcinoma. Toxic bile salts, cytokines, reactive oxygen species and drugs induce hepatocyte injury.
Hepatocyte injury can result in hepatocyte cell death via apoptosis and/or necrosis [2, 3]. Necrosis 
is a passive process associated with metabolic disruption and energy depletion (loss of ATP), leading 
to mitochondrial swelling and rupture of the plasma membrane. Subsequently, the cellular content 
is released into the extracellular environment and systemic circulation, triggering an inflammatory 
response in the liver. Apoptosis is an ATP-dependent process also known as programmed cell 
death. Apoptosis is characterized by DNA condensation, nuclear fragmentation, plasma membrane 
blebbing and cell shrinkage, resulting in the formation of apoptotic bodies. Apoptotic bodies are 
cleared by surrounding phagocytosing cells, limiting the inflammatory response [2-5]. 
Hepatocyte apoptosis is ubiquitous in liver diseases [1, 6-10]. Although apoptosis is primarily 
a non-inflammatory process responsible for removing excess or damaged cells, apoptosis in 
pathologic conditions is not controlled and can deteriorate organ function [11]. In the liver, 
apoptosis contributes to inflammation by promoting Kupffer cell activation. Following uptake of 
apoptotic bodies, Kupffer cells express death ligands such as TNFα, TRAIL and FasL [12]. All these 
death ligands may induce apoptosis in hepatocytes via death-receptor induced signaling cascades 
and thus aggravate liver injury [3, 13, 14]. In addition, activated myofibroblasts (derived from 
portal fibroblasts and HSCs [15, 16]) are able to engulf apoptotic bodies. Following engulfment 
of hepatocyte-derived apoptotic bodies, activated myofibroblasts produce profibrogenic cytokines 
such as TGFβ and type I collagen [17, 18]. Theses data link hepatocyte apoptosis to liver fibrosis in 
chronic liver diseases, suggesting that the most direct therapeutic strategy for repressing liver fibrosis 
is to eliminate the cause of hepatocyte injury. Many chronic hepatitis B patients with end-stage liver 
disease had significant recovery and reversal of liver fibrosis with antiviral therapy and no longer 
required urgent transplantation (reviewed by [19]). Therefore, removing the cause for hepatocyte 
injury has become a potential therapeutic strategy for advanced liver diseases. However, effective 
treatments do not exist for important liver diseases such as primary sclerosing cholangitis, NASH, 
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ASH and patients with chronic HCV or HBV unresponsive to antiviral therapies. For such patients, 
anti-apoptotic strategies, which reduce heptocyte injury-mediated inflammation and fibrogenesis, 
are beneficial [20-22]. Thus, understanding the cellular processes and molecular signaling pathways 
mediating hepatocyte apoptosis is essential to the development of new therapeutic strategies. In 
particular, the intracellular organelles and membrane receptors involved in hepatocyte cell death 
and their interactions are of substantial interest, as a single toxic stimulus often activates several 
intracellular apoptotic pathways simultaneously. In this review, recent advances in organelle- 




Mitochondrial dysfunction is a common observation in several acute and chronic liver diseases 
such as ASH, NAFLD, drug-induced hepatotoxicity, viral hepatitis, biliary cirrhosis, hepatocellular 
carcinoma, ischemia/reperfusion injury and transplant rejection [23]. Mitochondria play an essential 
role in regulating the intrinsic pathway of hepatocyte apoptosis as well as hepatocyte necrosis [3, 24-
28]. Mitochondrial permeability transition (MPT) is a key mechanism underlying both apoptosis 
and necrosis. MPT is characterized by an increase in the permeability of the inner mitochondrial 
membrane, resulting in the loss of membrane potential, mitochondrial swelling and the rupture of 
the outer mitochondrial membrane [26]. Opening of the permeability transition pore (mPTP) in 
the mitochondrial inner membrane is suggested to initiate the MPT. In addition, outer membrane 
channels such as mitochondrial apoptosis-induced channel (MAC) and the voltage dependent 
anion channel (VDAC) are directly or indirectly involved in mitochondrial permeabilization 
during apoptosis and/or necrosis [29]. Mitochondrial outer membrane permeabilization (MOMP) 
during intrinsic apoptosis leads to the release of apoptotic factors such as cytochrome c, Second 
Mitochondrial Activator of Caspase/Direct IAP Binding protein with Low pI (SMAC/DIABLO), 
High-Temperature Requirement protein A2 (HtrA2/Omi), Apoptosis-Inducing Factor (AIF) and 
endonuclease G [30, 31]. Subsequent activation of effector caspases leads to the proteolysis and 
typical morphological changes of apoptosis [32]. Although the molecular composition of  the 
mPTP is not completely known, three components are suggested to be directly or indirectly related 
to the mPTP: the outer membrane channel VDAC [33-35], the adenine nucleotide translocator 
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(ANT) [36] and cyclophilin-D [37], although studies with knockout animals have raised doubt 
about the involvement of ANT and VDAC in the mPTP [38, 39]. In addition, recent studies with 
cyclophilin-D deficient cells strongly suggest that mPTP opening is a consequence, rather than the 
cause for apoptosis, and validate the original proposal that the mPTP is key in necrotic cell death 
[37, 40, 41]. Furthermore, the observation that cytochrome c release can occur without the loss 
of outer membrane integrity indicates that a more selective mechanism of permeabilization such 
as the formation of a pore in the outer membrane instead of membrane rupture is operating in 
apoptosis [42-45]. The MAC forms early in apoptosis in the mitochondrial outer membrane and 
provides a direct pathway for the release of cytochrome c from the inter-membrane space into the 
cytosol. The MAC is tightly regulated by Bcl-2 family proteins and pro-apoptotic members of this 
family such as Bak and Bax are components of this channel [31, 42, 43, 43, 45-47]. However, the 
complete molecular structure of the MAC is not known and it is suggested that the MAC may 
contain additional components [31, 48]. Whatever their exact composition and function, both 
the mPTP and the MAC remain potential therapeutic targets to induce cell death in malignancies 
and prevent cell death in degenerative and ischemia-associated pathologies. Indeed, NIM811 (a 
non-immunosuppressor cyclosporine-analogue) is reported to decrease liver injury and induce 
liver regeneration by inhibiting MPT after liver transplantation or massive hepatectomy [49, 50]. 
NIM811 is also reported to attenuate cholestatic necrosis and apoptosis in BDL rats via inhibition 
of MPT [51]. Modulation of MPT in a multidrug-resistant hepatocellular carcinoma cell line with 
the selective MPT opener atractyloside glycoside (ATR) was shown to increase apoptosis in these 
cells whereas the selective inhibitor of MPT (Cyclosporine A) had the opposite effect [52]. These 
data suggest that targeting MPT is a potential therapeutic strategy for different liver diseases.
Endoplasmic Reticulum
ER stress is suggested to be an important mechanism in the pathogenesis of chronic liver 
diseases including NAFLD, ASH, viral hepatitis, drug-induced liver injury, ischemia/reperfusion 
injury and cholestatic liver disease  [53]. The ER is responsible for synthesis, folding, trafficking and 
maturation of proteins. Under pathologic conditions, the homeostatic equilibrium between the 
influx of the unfolded proteins and the folding capacity of the ER is disturbed, thereby activating 
signal transduction pathways between the ER and other intracellular organelles to mediate cellular 
adaptation to new demands. These series of compensatory responses, termed unfolded protein 
response (UPR), are conserved in the evolution and promote cellular survival [54]. Glucose 
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deprivation and the depletion of calcium stores can also induce ER-stress [55-57]. Three membrane 
sensors in the ER mediate the ER-stress signal transduction: inositol-requiring enzyme-1α (IRE1α), 
Activating Transcription Factor (ATF) 6 and Protein kinase RNA-like Endoplasmic Reticulum 
Kinase (PERK). These transmembrane sensors are kept inactivate as long as they are bound to 
the intraluminal chaperone Glucose-Regulated Protein 78 (GRP78)/BIP [58, 59]. IRE1α is an 
endoribonuclease that promotes the splicing of X-box binding protein 1 (XBP1) mRNA, resulting 
in transcription of UPR elements and ER-stress response genes that control ER-associated protein 
degradation (ERAD) and chaperones [60-62]. PERK induces phosphorylation of eukaryotic 
translation initiation factor-2α subunit (eIF2α), thereby globally inhibiting protein synthesis 
[63]. PERK also regulates the transcription of ribosomal RNA via phosphorylation of eIF2 and 
thereby increases the translation of ATF4. In turn, ATF4 binds to the cAMP-response element 
(CRE) resulting in the synthesis of C/EBP (CCAAT/enhancer binding protein) homologous 
protein (CHOP) [58, 64, 65]. Active ATF6, following translocation to the Golgi apparatus and 
RIP (Regulated Intramembrane Proteolysis) translocate to the nucleus and together with sXBP1 
and ATF4, activate ER-stress response elements, UPR elements and CRE [66-68]. Upon ER-stress, 
GRP78 is displaced from the stress sensor to aid in protein folding, leading to the activation of these 
three ER-stress mediated signaling pathways (i.e. IRE1α, ATF6 and PERK pathways). Prolonged 
or unchecked ER-stress leads to steatosis, apoptosis and inflammation in the liver [53]. An 
important feature of the ER-stress response is increased CHOP expression leading to the activation 
of proapoptotic pathways [69]. Overexpression or microinjection of CHOP protein have been 
reported to promote cell cycle arrest and/or apoptosis [70, 71]. CHOP can induce the expression 
of proapoptotic BH3-only protein Bim and the cell surface death receptor TRAIL receptor 2 (also 
known as death-receptor 5, DR5) and inhibit Bcl-2 transcription [72-74]. CHOP-knockout mice 
are protected against alcohol-induced hepatocyte apoptosis after alcohol feeding as well as against 
bile salt-induced hepatocyte apoptosis after bile duct ligation [75, 76]. Acetaminophen (APAP) 
intoxication has been observed to induce CHOP expression and to cause an intraluminal redox 
imbalance of the ER, resulting in hepatocyte apoptosis [77]. Importantly, the role of ER stress in 
APAP-induced necrosis is unknown, although a role in the early activation of JNK and in Ca2+-
mediated mitochondrial permeability transition, both key factors in APAP-induced necrosis [78, 
79], could be considered.
Several therapeutic interventions, such as chemical chaperones which ameliorate protein 
folding and antioxidants which counteract oxidative stress, could modulate ER-stress. E.g. the 
chemical chaperone 4-phenylbutyrate (4PBA) is able to reduce the ER-stress response and decrease 
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ER-associated caspase 12 activation in livers of mice undergoing ischemia-reperfusion injury 
[80]. CHOP antagonism is also an obvious target for therapy as CHOP is involved in oxidative 
stress and apoptosis in hepatocytes. Improved protein folding would be of benefit in disorders of 
misfolded proteins such as alpha-1-antitrypsin deficiency. Thus agents that ameliorate ER-stress 
by promoting adaptive UPR signaling or inhibiting ER-stress response-induced apoptosis offer 
a therapeutic opportunity. Since the ER-stress response has extensive cross-talk with other stress 
responses, therapeutics aimed at blunting the ER stress response may interrupt this interorganellar 
cross-talk that operates in many liver diseases [53]. 
Lysosomes
Lysosomes are involved in necrotic, apoptotic and autophagic cell death. The key factor in 
determining the type of cell death is the magnitude of lysosomal membrane permeabilization 
(LMP) and the amount of proteolytic enzymes released into the cytosol [81]. Massive breakdown 
of lysosomes results in unregulated necrosis, whereas selective permeabilization of lysosomes 
triggers apoptosis. Several mechanisms for the controlled permeabilization of lysosmes have been 
proposed. One theory includes the accumulation of lysosomotropic detergents such as sphingosine 
in the lysosomes, facilitating the release of lysosomal enzymes into the cytoplasm [82]. Another 
theory involves ROS-mediated lysosomal destabilization. In this theory LMP is suggested to 
precede mitochondrial dysfunction, thereby creating a feedback loop between mitochondrial-
derived ROS and LMP to control cell death. In addition, intralysosomal accumulation of free iron 
indirectly mediates lysosmal membrane damage via generation of ROS [83, 84]. Translocation of 
proapoptotic members of the Bcl-2 family such as Bax and Bim to the lysosomes, leading to pore 
formation and membrane permeabilization (similar to their role in mitochondrial permeabilization) 
is also proposed as a mechanism for lysosomal leakage [85-88]. LMP associated with cathepsin 
translocation may directly activate calpains and caspases, triggering classic MOMP- and caspase-
dependent apoptosis and/or caspase-independent cell death [89]. Increased lysosomal enzyme 
activity (e.g., acidic phosphatase) is observed in patients with chronic liver diseases including chronic 
viral hepatitis, cirrhosis and hepatocellular carcinoma [90]. In addition, LMP and cathepsins have 
been implicated in cell death in several models of liver injury. For instance, it has been shown that 
intracellular levels of sphingosine in the liver increases after TNFα treatment, leading to LMP 
and apoptosis. Interestingly, TNFα or sphingosine could not induce LMP in hepatocytes from 
cathepsin-B knockout livers, suggesting that cathepsins may also be inducers of LMP. Cathepsins 
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may directly induce LMP acting from the inside and/or outside of the lysosomes or they may 
participate in an amplification loop in which LMP induces cathepsin activation, and cathepsin 
then triggers further LMP [88, 91]. Free fatty acids and bile salts can also induce LMP-dependent 
cell death [92-95]. Glycochenodexycholic acid (a cholestatic bile salt) induces LMP, cathepsin-B 
translocation, caspase activation and cell death in hepatocytes in animal models of cholestasis [92, 
96]. Excessive accumulation of saturated free fatty acids in the liver has been reported to directly 
induce mitochondrial dysfunction and oxidative stress via LMP and activation of cathepsin B 
[95]. Translocation of non-heme iron from lysosomes to the mitochondria is reported to play an 
important role in oxidative-stress induced hepatocellular damage, identifying this pathway as a 
potential therapeutic target to combat oxidative stress-mediated hepatotoxicity [97]. Cymotrypsin 
B, a lysosomal enzyme originally described in pancreas, was also found in rat liver lysosomes. 
Interestingly, cymotripsin B was reported to cleave the non-apoptotic Bid into pro-apoptotic 
truncated Bid (tBid) at neutral pH. tBid then translocates to mitochondria, leading to MOMP 
and cytochrome c release. Knockdown of cymotripsin B or pretreatment with the cymotripsin 
B inhibitor, N-p-tosyl-L-phenylalanine chloromethyl ketone, reduced TNFα-induced apoptosis 
in hepatocytes [98]. As noted before for ER-stress, it is important to appreciate that disturbances 
in redox status, steatosis, oxidative stress, inflammation and mitochondrial injury all affect LMP. 
Interorganellar signaling pathways, death-receptor mediated signaling and lysosomal proteases such 
as cathepsin B can all be activated by LMP. Therefore, therapeutics aimed at reducing LMP may 
interrupt all these signaling pathways, thereby reducing liver inflammation and hepatocyte damage.
Receptor-mediated cell death 
Membrane death receptors
Death receptors belong to the TNF/Nerve Growth Factor superfamily and are involved in 
death ligand-mediated cell death. TNFα, Fas ligand (FasL) and Tumor necrosis factor-Related 
Apoptosis-Inducing Ligand (TRAIL) are death ligands that signal via binding to their membrane-
bound receptors including: Fas, Tumor Necrosis Factor Receptor  (TNFR1 and TNFR2), and 
TRAIL receptors (R1/DR4 and R2/DR5). Receptor-ligand binding triggers receptor trimerization 
at the cell surface, providing a platform at the cytoplasmic side of the plasma membrane (termed 
Death Domains) which recruits adaptor proteins such as Fas-associated death domain (FADD). 
The interaction between the death domains (DD) of death receptors and adaptor proteins leads 
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to the activation of caspase-8 and subsequent cleavage of Bid to tBid. Translocation of tBid to 
mitochondria results in mitochondrial permeabilization and activation of the apoptotic cascades. 
In addition, TNFα-induced Bid-dependent and TRAIL-induced Bax-dependent LMP has been 
described. LMP then leads to cell death [88, 99]. Although death receptors do not induce ER 
stress, ER stress-mediated regulation of TRAIL receptor (DR5) expression has been reported [73, 
100]. Therefore, interaction between death receptor signaling and intracellular organelles plays an 
important role in cell death. 
Several liver cells including hepatocytes express Fas (CD95/ Apo-1) [101-103]. Fas is activated 
upon binding of membrane-bound FasL or soluble FasL. FasL is expressed on several immune 
cells including cytotoxic T lymphocytes and natural killer (NK) cells [104]. FasL then activates 
Fas-mediated cell death, leading to the removal of unwanted hepatocytes such as virus-infected 
hepatocytes and cancer cells by immune cells [105]. However, excessive Fas-induced cell death 
leads to liver failure. Indeed, injection of Fas agonistic antibody to mice induces fulminant hepatic 
failure. In addition, it was shown that this toxicity is regulated by anti-apoptotic and pro-apoptotic 
Bcl-2 members [106-108]. Elevation of soluble FasL occurs in patients with acute liver failure (such 
as drug-induced liver injury and acetaminophen-induced liver injury) and FasL and/or Fas receptor 
expression is increased in many chronic liver diseases including chronic viral hepatitis and alcoholic 
liver diseases [109-112]. In summary, Fas/FasL induced apoptotic cell death plays a crucial role in 
liver pathogenesis.
TNFR1 and TNFR2 are both expressed on hepatocytes, but only TNFR1 expresses a DD [113]. 
Importantly, TNFR1 activation in hepatocytes can trigger both apoptotic and survival signaling. 
TNFα-exposure leads to the rapid formation of a DISC (Death Inducing Signaling Complex) 
composed of TNFα, the TNFR-associated death domain adaptor molecule (TRADD), the Fas-
associated death domain adaptor molecule (FADD), caspase-8, TNFR-associated factor -2 (TRAF2) 
and receptor-interacting protein (RIP). Interestingly, it was shown that TNFR1 and some DISC 
components also appear inside mitochondria within 30 minutes after TNFα-exposure, suggesting 
that TNFα-mediated signaling includes the translocation of TNFR1 (and associayed proteins) to 
mitochondria [114]. In contrast, TRADD suppresses apoptosis by recruiting RIP, TRAF2 and 
TRAF5. Immediate binding of RIP and TRAF2 to TRADD lead to the activation of Nuclear 
Factor-κB (NF-κB) and transcriptional activation of prosurvival genes including Bcl-xL, A1, XIAP 
and cFLIP [115, 116]. TNFα/TNFR2 signaling is involved in the activation of hepatocyte DNA 
synthesis and proliferation as well as in the regulation of  FasL-dependent clearance of virus infected 
hepatocytes by cytotoxic T lymphocytes (CTL) [117, 118]. Interestingly, mice lacking both TNFR1 
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and TNFR2 are resistant to anti-Fas induced-fulminant hepatic failure [119]. These data suggest 
that TNFα/TNFRs interactions are critical for the proper functioning of CTL activity in the liver 
and clearance of infected and/or damaged hepatocytes.
TRAIL is emerging as a key mediator of hepatic injury during inflammatory disorders of the 
liver [120]. Early studies demonstrated that different cells have different sensitivity to TRAIL-
induced cell death. Whereas cancer cells are sensitive to TRAIL-induced toxicity, normal (non-
transformed) cells were resistant to its apoptosis-inducing effects. Hence, TRAIL-induced selective 
cancer cell death without damage to the adjacent normal tissue was suggested to be an efficient 
anti-cancer therapy [121, 122]. Indeed, TRAIL, DR4 and DR5 (TRAIL receptors) messenger 
RNA are expressed at low levels in normal human liver and the expression of the receptors at the 
protein level is difficult to detect. However, emerging data indicate that DR4 and DR5 expression 
is upregulated in several liver diseases such as steatosis and HCV- and HBV-infection [123-126]. 
HIV and/or the ligation of HIV glycoprotein gp120 to CXCR4 on hepatocytes also selectively 
increases DR5 expression and suggest that HIV infection renders hepatocytes more susceptible 
to apoptotic cell death in liver diseases associated with enhanced TRAIL expression such as HBV, 
HCV or steatohepatitis [127]. Increased DR5 expression in experimental models of NASH is 
associated with the activation of p53 and ER-stress induced CHOP expression by free fatty acids 
such as palmitate [128, 129]. In addition, bile acids can increase DR5 expression and inhibit cFLIP 
(inhibitor of DR5-induced signaling) function, thereby sensitize hepatocytes to TRAIL mediated 
cell death in cholestatic livers [130, 131]. Thus, the safety of TRAIL administration to humans with 
underlying liver disease is questionable. The development of selective DR4 agonistic antibodies to 
treat cancer in patients with underlying liver diseases could be an attractive strategy, considering the 
possibility of DR5-dependent TRAIL toxicity in liver diseases. 
In summary, excessive generation of inflammatory mediators and activation of death-receptor 
mediated apoptotic pathways can exacerbate underlying liver diseases. Therefore, therapies targeting 
death receptor-mediated hepatotoxicity in combination with efforts to remove the cause of the 
disease (e.g., virus, toxic bile acids, free fatty acids and drugs) may be a beneficial strategy in the 
treatment of liver diseases.
Epidermal growth factor receptor
The epidermal growth factor receptors (EGFR; ErbB-1; HER1 in humans) are the cell-surface 
receptors for members of the epidermal growth factor family (EGF-family) of extracellular protein 
12
Chapter 2
ligands. The EGFR is a member of the ErbB family of receptors, a subfamily of four closely related 
receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2),Her 3 (ErbB-3) and Her 4 
(ErbB-4) [132]. Growth factor receptors such as the EGFR are involved in both cell proliferation 
and cell death in the liver [133]. EGF functions as an endocrine factor. It is produced by a variety 
of cells and EGF/EGFR interaction is essential for liver regeneration [134]. Ligand-dependent 
EGFR activation also plays a role in hepatic tumorigenesis and EGFR-targeting agents such as 
monoclonal antibodies (e.g., cetuximab and panitumumab) and tyrosine kinase inhibitors (e.g., 
gefitinib and erlotinib) are suggested in the treatment of liver carcinomas [135, 136]. In addition 
to ligand-dependent EGFR activation, ligand-independent EGFR activation in the liver has been 
described. For instance, hydrophobic bile acids induce reactive oxygen species (ROS)-dependent 
EGFR tyrosine phosphorylation in hepatocytes, leading to the activation of downstream mitogen-
activated protein kinases (MAPK) [14]. Hydrophobic bile acids also induce extracellular kinase 
regulated (ERK)-dependent hepatic stellate cell (HSC) proliferation via ROS-dependent EGFR 
activation [137]. As described above, ligand-independent EGFR activation plays an important 
role in liver pathogenesis. In hepatocytes, ligand-independent EGFR activation also contributes to 
apoptosis [133]. Several mechanisms for ligand-independent EGFR activation have been described 
such as EGFR transactivation by Fas ligand (FasL)[138, 139], hydrophibic bile salts (deoxycholate, 
glychocenodeoxycholate, etc) or hyperosmolarity [14, 138, 139]. Ligand-independent activation 
of EGFR is followed by JNK-dependent EGFR/Fas association, a process that requires ROS-
dependent Yes activation, followed by Yes-mediated EGFR transactivation [138-142]. EGFR/Fas 
association results in EGFR-mediated tyrosine phosphorylation of Fas (death receptor), leading to 
Fas oligomerization, membrane translocation, DISC formation and execution of apoptosis [138, 
139, 143]. 
These data suggest that agents that inhibit ligand-independent activation of EGFR such as 
tyrosine kinase inhibitors may have substantial anti-apoptotic effects in hepatocytes. Interestingly, 
recent evidence suggests that the EGFR can also function as a host cofactor for HCV entry and 
tyrosine kinase inhibitors show substantial antiviral activity [144]. Chronic viral hepatitis is 
associated with activation of inflammatory mediators and accumulation of immune cells in the 
liver which can induce hepatocyte apoptosis/necrosis in non-infected hepatocytes via activation 
of death-receptor signaling pathways. Thus inhibition of receptor tyrosine kinase (such as EGFR) 
may constitute an attractive novel approach in the treatment of chronic liver diseases, in particular 
chronic viral hepatitis due to their antiviral activity and anti-apoptotic effects in healthy hepatocytes. 
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G-protein coupled receptors 
GPCRs are the largest family of membrane proteins. More than 300 GPCRs have been reported 
in humans and rodents [145]. GPCRs transduce extracellular signals to intracellular effector 
pathways. Upon activation by agonists, GPCRs activate heterotrimeric G-proteins (Gαβγ). These 
subunits subsequently activate second messengers (e.g. cAMP, Ca2+ and protein kinases), relaying 
the GPCR induced-signal to the intracellular targets. Heterotrimeric G-proteins are divided into 4 
families (i.e., Gαs, Gαi, Gαq/11 and Gα12/13) based on the Gα subunit sequence and signaling 
activity [146]. Many GPCRs such as lysophosphatidic acid (LPA), sphingosine-1 phosphate 
(S1P) and orexin (OXR) receptors are involved in the regulation of apoptosis in cancer cells [147-
149]. Signaling components acting downstream of the GPCRs or G-proteins (e.g., arrestin and 
adaptor protein 2) may mediate anti-apoptotic events following stimulation of GPCRs [150, 151]. 
Activation of GPCRs regulates apoptosis in cancer cells via interaction with different intracellular 
regulators of apoptosis such as MAPKs, NF-κB and p53- associated pathways [152]. E.g., LPA-
dependent signaling decreases the nuclear localization and cellular abundance of p53, leading 
to resistance of lung carcinoma cells to apoptosis [153]. Stimulation of endogenous muscarinic 
receptors in SH-SY5Y cells (human neuroblastoma cell line) was able to inhibit p53 translocation 
to the mitochondria and p53 phosphorylation at serine 15 and 37, thereby protecting these cells 
against DNA-damaging agents [154]. Activation of the receptors for LPA, ET1 (endothelin) and 
angiotensin II can activate NF-κB-regulated pathways. NF-κB then mediates either anti-apoptotic 
or pro-apoptotic responses, depending on the stimulus and the cell type [115, 155-158]. In the 
liver, activation of GPCRs also mediates both apoptotic and anti-apoptotic responses. E.g., S1P 
receptors mediate both apoptotic and anti-apoptotic pathways in human hepatic myofibroblasts 
[159]. Free fatty acids such as palmitic acid mediate apoptosis in hepatocytes via phospholipase 
A2 (PLA2)/lysophosphatidylcholine (LPC)/LPA-dependent signaling [160]. However, the exact 
signaling pathways downstream of GPCRs that regulate apoptosis in hepatocytes are yet unknown. 
Nevertheless, excellent therapeutic benefits have been observed with some GPCR-based drugs 
in cancer therapy: the endothelin A receptor antagonists -ZD4054 and atrasentan- show potent 
antitumor efficacy for ovarian and prostate cancer [152, 161-163]. GPCR-based drugs may also 
show therapeutic benefits in the regulation of apoptosis in chronic liver diseases and liver tumors. 
Conclusions
Understanding the cellular mechanisms that control death in hepatocytes is of clinical and 
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scientific importance in the development of novel therapies. Hepatocyte cell death appears to be 
at the cross-roads of several cellular mechanisms rather than the end-point of a linear cascade of 
events. One particular toxic stimulus may simultaneously promote the activation of several types of 
membrane-bound receptors as well as organelle-mediated signaling pathways, leading to apoptosis. 
In addition, several toxic stimuli often play a role in the pathogenesis of chronic liver diseases (e.g., 
free fatty acids and inflammatory mediators in NASH). Thus, anti-apoptotic therapeutics aimed at 
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Mitochondrial permeability transition pore proteins are up-regulated in fatty 
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Background & Aim: Excessive hepatocyte death in non-alcoholic fatty liver disease (NAFLD) 
triggers inflammatory responses in the liver. Mitochondrial permeability transition (mPT) is the 
crucial event in the regulation of cell death and is initiated by mPT pore (mPTP) opening. Up-
regulation of mPTP proteins results in increased susceptibility to cell death, in particular necrosis. 
Whether expression of mPTP proteins is changed in fatty hepatocytes is not known. Here, we 
analyzed the expression pattern of mPTP proteins in fatty hepatocytes and we studied their 
susceptibility to apoptotic and necrotic cell death.
Methods: Expression of the mPTP proteins VDACs (Vdac1-3), ADP/ATP translocase (Ant-1) 
and Cyclophilin D (Ppid) was analyzed in hepatocytes isolated from leptin receptor-deficient 
Zucker rats, an established model of NAFLD, with lean Zucker rats serving as controls. Primary 
hepatocytes were exposed to glycochenodeoxycholic acid (GCDCA) and tumor necrosis factor-α 
(TNFα)/actinomycin D (ActD) to induce apoptosis. Apoptosis (caspase-3 activity, acridine orange 
staining) and necrosis (LDH leakage, Sytox green staining) were quantified.
Results: mRNA and protein expression of Ant-1 and Ppid were significantly increased in fatty 
hepatocytes. Compared to lean hepatocytes, fatty hepatocytes showed an increased level of necrosis 
during standard culture conditions (P<0.05), even though their viability directly after isolation was 
the same. In contrast, fatty hepatocytes showed a reduced sensitivity towards GCDCA-induced 
apoptosis, while their susceptibility to TNFα/ActD-induced apoptosis was unchanged.
Conclusion: Cyclophilin D and Ant-1, two crucial components of mPTP, are up-regulated in fatty 
hepatocytes, which coincides with a clear increase in the susceptibility to necrosis.





Non-alcoholic fatty liver disease (NAFLD) is a common feature of the metabolic syndrome. 
The prevalence of NAFLD is increasing worldwide and is estimated to affect approximately 20% 
of the population in developed countries [1]. Histopathological features of NAFLD range from 
simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is characterized by the presence 
of inflammation in addition to steatosis and may progress to cirrhosis, hepatocellular carcinoma, 
and eventually death [2]. Fatty livers are vulnerable to injury from various causes and the liver-
related morbidity and mortality increases substantially once hepatitis develops [3, 4]. Therefore, 
the transition from steatosis to steatohepatitis is an important event in the progression of chronic 
fatty liver disease. By inducing hepatocyte injury, lipotoxicity, oxidative stress, pro-inflammatory 
cytokines, bacterial lipopolysaccharides and cholestasis may all trigger the progression of steatosis 
to steatohepatitis [1]. 
Hepatocyte injury is one of the important features observed in NASH [2]. Hepatocyte death 
can happen via apoptosis, necrosis or a combination of both modes of cell death. Apoptosis results 
in the fragmentation of the cell into apoptotic bodies, which are cleared  by surrounding phagocytes 
thereby minimizing inflammation during liver injury [5]. Necrosis leads to mitochondrial and 
cellular swelling, the rupture of the plasma membrane and the subsequent release of the cellular 
content into the extracellular environment, resulting in an inflammatory response in the liver 
[5]. Mitochondria play a crucial role in both types of cell death [6]. Onset of the mitochondrial 
permeability transition (mPT) is suggested to be the common mechanism for both apoptosis and 
necrosis. Opening of permeability transition pores (mPTP) in the mitochondrial membrane is one 
of the initiating events in the mPT [7-9]. Pore opening leads to a non-selective diffusion of proteins 
across the mitochondrial membrane and subsequently cell death [8-10]. Importantly, it is suggested 
that mPTP plays a crucial role in necrosis rather than apoptosis [11, 12] and cells overexpressing 
the mPTP-associated protein, Cyclophilin D, are more susceptible to necrotic cell death [13]. In 
addition, mice overexpressing Cyclophilin D show mitochondrial swelling and spontaneous cell 
death in vivo [14]. Mitochondrial dysfunction and alterations in mPT have been suggested as 
predisposing mechanisms in the transition from steatosis to steatohepatitis (likely via modulating 
hepatocyte cell death in fatty livers) [15-18]. In the present study, we demonstrate that mPTP 
proteins, Cyclophilin D and Ant-1, are up-regulated in fatty hepatocytes from Zucker rats resulting 
in a predisposition of these cells to necrosis even under control conditions in the presence of normal 
32
Chapter 3
cellular and extracellular ATP levels. We further demonstrate that fatty hepatocytes show a reduced 





Specified pathogen-free male Zucker rats (fa/fa) and their corresponding lean (FA/FA or FA/
fa) male littermates (8-10 weeks of age) were purchased from Charles River Laboratories Inc. 
(Wilmington, MA, USA). Animals were caged in animal rooms with alternating 12-hour light/
dark period, free access to standard laboratory chow and water for 2 weeks. Fatty Zucker rats and 
lean Zucker rats were weighed prior to the hepatocyte isolation. All experiments were performed 
in accordance with the guidelines of the local Committee for Care and Use of laboratory animals.
Rat hepatocyte isolation 
Hepatocytes were isolated from Zucker fatty rats and Zucker lean controls and cultured in 
multiwell plates (Greiner bio-one) in William’s E medium in a humidified incubator at 37 ºC and 
5% CO2 as described before [19]. Aliquots of approximately 1 million cells were snap-frozen in 
liquid nitrogen immediately after isolation (t0 hepatocytes) for RNA and protein analysis.
Experimental design
 
Experiments were started after the attachment period of 4 hours. Monolayers of cultured 
primary hepatocytes were treated with 50-200 µmol/L GCDCA (Sigma-Aldrich) for 2- 4 hours. 
Alternatively, hepatocytes were treated for 16 hours with 20 ng/ml recombinant murine tumor 
necrosis factor α (mTNFα, R&D Systems, Abingdon, UK) in combination with 200 ng/ml of 
the transcriptional inhibitor actinomycin-D (Roche Diagnostics, Almere, the Netherlands). 
Actinomycin D was added to cultured hepatocytes 30 minutes prior to the apoptotic stimulus. 
Every experimental condition was performed in triplicate and each experiment was repeated at least 
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three times using hepatocytes from different rats. Cells were harvested at the indicated time points 
as described previously [20]. Hepatocytes were isolated from different fatty Zucker rats (n = 9) and 
lean Zucker rats (n = 8).
Hepatocyte triglyceride measurement
Cellular triglyceride content was determined in t0 hepatocytes with a commercially available kit 
(Wako Chemicals, Neuss, Germany) after lipid extraction as described before [21].
ATP measurement
Rat hepatocytes were cultured in 96-well plates. Cells were treated according to the experimental 
design after the attachment period of 4 hours. ATP levels were measured using the Cell Viability 
Kit (CellTiter-GIo® Luminescent Assay, Promega, Madison, USA) according to the manufacturers 
instruction.
Apoptosis and necrosis assays 
Caspase-3 activity was measured as described previously [20]. The arbitrary fluorescence unit 
(AFU) was corrected for the amount of protein. Protein concentration was determined using the Bio-
Rad protein assay kit. LDH release from hepatocytes was measured in the supernatant of medium 
of cultured cells at different time points after hepatocyte isolation. LDH activity was determined 
spectrophotometrically at 340 nm. Sytox green (Invitrogen) and acridine orange (Sigma-Aldrich) 
were used to visualize necrotic and apoptotic cell death, respectively, as described before [19]. 
Quantitative PCR
RNA isolation, reverse transcription PCR and quantitative PCR (qPCR) were performed as 
described previously [19]. Each sample was analyzed in duplicate. 18S mRNA levels were used as 
endogenous control. Primers and probes are listed in Table 1.
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Assay on Demand: Rn01458749 (Invitrogen)
Western-blot analysis
Western blot analysis was performed as described previously [19]. Expression of selected proteins 
was assessed using polyclonal rabbit antibodies against Cyclophilin D (Ppid; Thermo Scientific), 
Ant-1 (Thermo Scientifc) or monoclonal rabbit antibody against total Vdac (Cell Signaling) at a 
dilution of 1:1000. Horse radish-peroxidase conjugated goat anti-rabbit Ig (DAKO, Denmark) was 
used as a secondary antibody at a dilution of 1:2000. 
Statistical analysis 
Results are presented as the mean of at least 3 independent experiments ± SD. Student t-test 
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or ANOVA were used to determine the significance of differences between experimental groups. A 
P-value of less than 0.05 (P<0.05) was considered statistically significant.
 
Results
Zucker fatty rats have a higher hepatic triglyceride content compared to lean rats
The Zucker fatty (fa/fa) rat is genetically homozygous for a mutation in the leptin receptor 
gene and hence develops severe obesity, hyperinsulinemia and fatty liver disease [22]. NAFLD is 
characterized by the accumulation of triglycerides (TG) within hepatocytes. In accordance, obese 
(fa/fa) rats at the age of 10-12 weeks were significantly heavier than lean (FA/fa; FA/FA) control rats 
prior to the hepatocyte isolation (335 ± 82.66 vs. 255 ± 61.84 gr, respectively, P < 0.05, Figure1A). 
We then measured the triglyceride (TG) content in hepatocytes directly after the isolation (t0 
hepatocytes). Fatty hepatocytes had almost 4-fold higher amounts of TG compared to hepatocytes 
from lean controls (3.917 ± 1.826 vs. 1.061 ± 0.7149 mmol TG/ mg protein, respectively, P< 0.05; 
Figure1B). 
A B
Figure1: Zucker fatty rats are heavier than Zucker lean rats and hepatocyte triglyceride (TG) content is increased. 
(A) Body weight of Zucker fatty rats (n = 9) and Zucker lean rats (n = 8) was measured at the age of 10-12 weeks prior 
to the hepatocyte isolation. (B) The TG content was determined in hepatocytes from fatty and lean rats directly after 
isolation (t0 hepatocytes). The TG content (mM) was corrected for the amount of protein (mg) and expressed as mM/
mg.
Mitochondrial permeability transition pore (mPTP) proteins are higher expressed in fatty hepatocytes 
compared to lean hepatocytes predisposing them to necrosis 
The mPTP is known to be a regulator of mitochondrial integrity during cell death. Recent 
studies have linked the mPTP to events of late apoptosis and necrosis [7, 9]. Overexpression of the 
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mPTP protein Cyclophilin D (Ppid) increases the susceptibility of cells to necrosis [13, 23]. We 
compared the expression of the mPTP-associated proteins Cyclophilin D (Ppid), voltage-dependent 
anion channel (Vdac: isoforms 1-3) and adenine nucleotide translocator (Ant: isoforms 1 and 2) in 
t0 fatty hepatocytes and t0 lean hepatocytes. Interestingly, fatty hepatocytes expressed significantly 







Figure2: mPTP related proteins are up-regulated in fatty hepatocytes and fatty hepatocytes are more susceptible 
to necrosis than lean hepatocytes. (A) Expression pattern of mPTP proteins in fatty and lean hepatocytes. Q-PCR 
analysis for Vdac-1, Vdac-2, Vdac-3, Ant-1, Ant-2 and Cyclophilin D (Ppid) using total RNA isolated from fatty and 
lean hepatocytes immediately after isolation (t0 hepatocytes). * P < 0.05 for fatty hepatocytes vs lean hepatocytes. (B) 
Western-blot analysis for Cyclophilin D (Ppid), Ant-1 and total Vdac in cell lysates of t0 hepatocytes isolated from fatty 
and lean rats. Equal amounts of protein were loaded. (C) LDH leakage was determined in the supernatant of cultured 
fatty and lean hepatocytes at the indicated time points. * P<0.05 fatty hepatocytes vs lean hepatocytes. (D) Necrotic 
hepatocytes visualized by Sytox green staining at 16 h after the hepatocyte isolation. Lean hepatocytes (left panels) and 
fatty hepatocytes (right panels). (E) Caspase-3 activity in cultured fatty and lean hepatocytes at indicated time points. 
Caspase-3 activity is expressed as percentage of the caspase-3 activity in lean hepatocytes at 6 h.
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The fatty hepatocytes also expressed higher protein levels of Cyclophilin D (Ppid) and Ant-1 
compared to the lean hepatocytes, whereas there was no difference in the protein expression of total 
Vdac in both types of hepatocytes (Figure2 B). These data indicate that Cyclophilin D and Ant-1, 
two crucial components of mPTP [9], are up-regulated in fatty hepatocytes even under baseline 
conditions which may predispose fatty hepatocytes to necrosis. 
LDH leakage from hepatocytes is an indicator of cellular necrosis [24, 25]. We measured LDH 
leakage in the supernatant of cultured hepatocytes at 6 h, 8 h and 16 h after the hepatocyte isolation. 
The initial viability for lean and fatty hepatocytes was the same (80 %). However,  fatty hepatocytes 
released significantly more LDH into the medium compared to lean hepatocytes at all time points 
tested (P<0.05; Figure2 C), indicating that fatty hepatocytes are predisposed to necrosis even 
under normal conditions. In accordance, Sytox green staining showed that the number of necrotic 
fatty hepatocytes at 16 h after isolation was increased compared to lean hepatocytes (Figure2 D). 
Importantly, caspase-3 activity in both fatty and lean hepatocytes was equally low at these time 
points (Figure2 E), indicating that the isolated hepatocytes were not apoptotic. 
Fatty hepatocytes show reduced susceptibility to GCDCA-induced apoptosis compared to lean 
hepatocytes, despite similar total ATP levels
GCDCA (50 µM) induces caspase-3 activity in fatty and lean hepatocytes peaking at 2 h 
(data not shown). We compared the effect of different concentrations of GCDCA (50-200 µM) 
in fatty and lean hepatocytes at this time point. The GCDCA-induced caspase-3 activity in fatty 
hepatocytes was significantly lower (50%, P<0.05) compared to lean hepatocytes at 50 µM and 
100 µM GCDCA (Figure3 A), indicating that fatty hepatocytes show decreased GCDCA-induced 
apoptosis compared to lean hepatocytes. At higher GCDCA concentration (200 µM) the primary 
mode of cell death shifts to necrosis [19] and thus less caspase-3 activity is detected in both lean and 
fatty hepatocytes (Figure3A). To establish true apoptosis, GCDCA-treated hepatocytes were stained 
with acridine orange after 2 hours exposure to 50-200 µM GCDCA. Cellular blebbing, nuclear 
fragmentation and condensation, all markers for end-stage apoptosis, were readily detectable at 
the concentration of 50 µM GCDCA in lean hepatocytes and increased upon exposure to higher 
concentrations of GCDCA (Figure3B). In contrast, these features of apoptosis were not present in 
fatty hepatocytes upon exposure to 50 µM GCDCA and were less prominent in fatty hepatocytes 
upon exposure to higher GCDCA concentrations compared to lean hepatocytes (Figure3B) 
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confirming that fatty hepatocytes show reduced sensitivity to GCDCA-induced apoptosis.




Figure3: Fatty hepatocytes show reduced susceptibility to glycochenodeoxycholic acid (GCDCA)-induced 
apoptosis, which is not due to lower basal ATP levels or an altered decline pattern of ATP following GCDCA 
exposure. (A) Caspase-3 activity in primary rat hepatocytes. Fatty heptocytes and lean hepatocytes were exposed 
to 50-200 µ of GCDCA for 2 hours. * P < 0.05 for fatty hepatocytes vs lean hepatocytes. (B) Nuclear morphology 
and cellular blebbing of hepatocytes visualized by acridine orange staining. Nuclear fragmentation, condensation (red 
arrows) and cellular blebbing (white arrows) are less abundant in fatty hepatocytes (lower panels) compared to lean 
hepatocytes (upper panels) after a 2 h-exposure to various concentrations of GCDCA (50-200 µM). (C) Primary fatty 
hepatocytes and lean hepatocytes were cultured for 4 hours and subsequently exposed to 50-200 µM GCDCA for 1 
hour. The ATP concentration in these hepatocytes was measured 5 hours after isolation. (D) Primary fatty hepatocytes 
and lean hepatocytes were cultured for 4 hours and subsequently exposed to 50-200 µM GCDCA for 4 hours. The ATP 
concentration in these hepatocytes was measured 8 hours after isolation.
Hence, we measured total (cellular + extracellular) ATP levels, in the culture medium to 
determine whether the susceptibility of fatty hepatocytes to necrosis and the reduced sensitivity of 
fatty hepatocytes to GCDCA-induced apoptosis is caused by lower ATP level in fatty hepatocytes. 
Interestingly, both cultured fatty hepatocytes and lean hepatocytes had similar basal levels of ATP 
at 5 hours and 8 hours after isolation (Figure3C and D), suggesting that the higher susceptibility 
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of fatty hepatocytes to necrosis is not due to lower ATP levels in these cells. Next, we measured 
ATP levels in cultured hepatocytes after 1 hour and 4 hours exposure to various concentrations of 
GCDCA (50-200 µM). Again, there was no difference in the pattern of decline of ATP levels in 
both fatty and lean GCDCA-treated hepatocytes (Figure3C and D), suggesting that the reduced 
sensitivity of fatty hepatocytes to bile acid-induced apoptosis is not due to lower basal ATP levels or 
a different decline pattern in ATP during GCDCA-exposure.
Fatty hepatocytes do not show altered sensitivity to cytokine-induced apoptosis compared to lean 
hepatocytes 
Tumor necrosis factor-α in combination with actinomycin-D induces caspase-3 activity in 
primary rat hepatocytes [20] that peaks at 16 h in fatty and lean hepatocytes (data not shown). We 
compared the sensitivity of fatty and lean hepatocytes to TNFα/ActD-induced apoptosis at this 
time point. The caspase-3 activity assay and acridine orange staining revealed that both types of 
hepatocytes are equally sensitive to cytokine-induced apoptosis and that apoptosis is the dominant 
mode of cell death in this model (Figure4A and B).
 
A B
Figure4: Fatty hepatocytes do not show increased sensitivity to tumor necrosis factor-α/actinomycin-D (TNFα/
ActD)-induced apoptosis. (A) Caspase-3 activity in rat hepatocytes. Primary fatty hepatocytes and lean hepatocytes 
were treated for 16 hours with 20 ng/ml of TNFα in the presence of 200 ng/ml of ActD. (B) Acridine orange staining. 
Treatment with TNFα/ActD induces nuclear condensation, fragmentation and cellular blebbing in fatty hepatocytes 
(lower panels) and lean hepatocytes (upper panels).
Discussion
In this study, we report that Cyclophilin D (Ppid) and Ant-1, the two crucial components of 
the mPTP, are up-regulated in fatty hepatocytes. Moreover, fatty hepatocytes appear to be more 
susceptible to necrosis, but show a reduced sensitivity to GCDCA-induced apoptosis compared 
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to lean hepatocytes even in the presence of normal ATP levels. On the other hand, they do not 
show an altered sensitivity to TNFα/ActD-induced apoptosis. We suggest that the up-regulation of 
mPTP proteins plays a critical  role in the increased susceptibility of fatty hepatocytes to necrosis.
 Mitochondrial dysfunction and alterations in the mPT have been suggested to play a role 
in the development of steatohepatitis in NAFLD [16-18]. Importantly, mPTP opening (which 
initiates mPT) and up-regulation of mPTP proteins are suggested to initiate necrosis and increase 
spontaneous cell death in vivo [9, 13, 14, 23]. However, a detailed analysis of the expression of 
these proteins in fatty hepatocytes has not been described before. It is important to define the 
primary mode of cell death in fatty hepatocytes and the underlying mechanisms in order to develop 
effective therapeutic strategies aiming at minimizing the incidence of hepatocyte cell death-induced 
liver inflammation in NAFLD. We used hepatocytes isolated from Zucker obese rats as a model 
of NAFLD [22]. These hepatocytes contained higher TG levels than lean Zucker hepatocytes and 
hence serve as a good model for fatty hepatocytes in NAFLD. Directly after isolation, the viability 
of fatty hepatocytes was similar to the lean hepatocytes, however, a clear increased level of necrosis 
was detected upon culturing of the fatty hepatocytes.
Although apoptosis and necrosis are two distinct modes of cell death,  they share certain cellular 
and molecular features. Mitochondria are involved in both apoptosis and necrosis in hepatocytes [6, 8, 
27, 28]. An important step in mitochondrial-dependent cell death is the mitochondrial permeability 
transition (mPT). Permeabilization triggers the release of various proteins from mitochondria 
into the cytosol where they activate apoptotic and/or necrotic cascades. Opening of two different 
mitochondrial channels has been suggested to play a role in mitochondrial permeabilization: the 
permeability transition pore (mPTP) in the inner membrane and the mitochondrial apoptosis-
induced channel (MAC) in the outer membrane. Several studies have indicated that the mPTP 
is more important in necrosis than apoptosis [11, 12]. Opening of the mPTP results in non-
selective diffusion of solutes across the mitochondrial inner membrane, leads to mitochondrial 
depolarization, uncoupling of oxidative phosphorylation, swelling of mitochondria and eventually 
cell death [7-9]. Although the exact structure of the mPTP has not been elucidated yet, Cyclophilin 
D, ANT and VDAC have been suggested to be components of the mPTP [9, 12, 14, 23, 29]. It 
has been shown that cells containing higher amounts of Cyclophilin D are indeed hypersensitive 
to necrotic cell death [13]. In accordance, our data demonstrate that fatty hepatocytes are more 
susceptible to necrosis most likely due to the higher expression of Cyclophilin D. It has been 
shown that the ANTs are non-essential components of the mPTP. However, the ANTs do have an 
important role in regulating permeability transition by modulating the sensitivity of the mPTP to 
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[Ca 2+]-overload and ANT ligands [29]. Cyclophilin D is thought to facilitate a calcium-triggered 
conformational change in ANT, converting it into an open pore [11]. Therefore, the up-regulation 
of Ant-1 in fatty hepatocytes can also play a role in the increased susceptibility of fatty hepatocytes 
to necrosis. Some studies have suggested that the mPTP contains the outer membrane channel 
protein VDAC [30, 31]. However, a recent study in which all VDAC isoforms were knocked out 
have raised doubt about the involvement of outer membrane components in the mPTP as the 
knockouts still have a functional mPTP [32]. In other studies, VDAC oligomers were suggested 
to be directly responsible for cytochrome c release and apoptosis [33-35]. Our data showed an 
increase in mRNA expression levels of Vdac-1 and Vdac-3 in fatty hepatocytes compared to lean 
hepatocytes, but we were not able to detect a difference at the protein level between the two types of 
hepatocytes due to the lack of specificity of the available antibody for the Vdac isoforms. Whether 
the increase in mRNA expression level of Vdac-1 or Vdac-3 has an effect on the susceptibility 
of fatty hepatocytes to necrosis and/or apoptosis remains to be determined. Taken together, up-
regulation of Cyclophilin D and Ant-1 conceivably may be key events in hypersensitizing fatty 
hepatocytes to necrosis. 
It has been observed that Cyclophilin D null fibroblasts are not protected from TNFα-induced 
apoptosis, suggesting that cytokine-induced cell death is not dependent on Cyclophilin D and 
mitochondrial permeability transition [14]. This may explain why fatty hepatocytes do not show 
altered sensitivity to cytokine-induced apoptosis despite the up-regulation of mPTP proteins. 
Although the mPTP is central to necrosis, it can open transiently in response to insults such as 
oxidative stress and [Ca2+]-overload. In these situations, the transient mPTP opening may be 
sufficient to cause cytochrome c release and induce apoptosis. Mice overexpressing Cyclophilin 
D showed increased apoptosis of heart-muscle cells in vivo. These hearts were also enlarged and 
contained swollen, leaky mitochondria. This suggests that excess Cyclophilin D still leads to 
sufficient opening of pores to cause apoptosis [11, 14]. Importantly, Cyclophilin D and mPT are 
crucial for [Ca2+] overload-induced apoptosis and GCDCA-induced apoptosis in hepatocytes is 
associated with an increase in intracellular [Ca2+] [14, 36]. Transient mPTP opening, despite up-
regulation of mPTP proteins, may explain why fatty hepatocytes are still susceptible to bile acid-
induced apoptosis, although their sensitivity is reduced even in the presence of normal ATP levels. 
This finding is in accordance with a previous report indicating that fatty hepatocytes may show a 
reduced sensitivity to GCDCA-induced apoptosis and are more susceptible to necrosis. Although 
the mechanisms are not completely known, alterations in mPT have been suggested to contribute 
to  these findings [25]. 
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Some studies have shown that treatment of fatty hepatocytes with mPTP inhibitors such as 
cyclosporin A (CSA), an inhibitor of cyclophilins, protects fatty hepatocytes against bile acid-
induced necrosis [25, 37]. Although we have not tested these compounds in this study, such 
beneficial effects of mPTP inhibitors are lending indirect support to our proposed mechanism 
that fatty hepatocytes are vulnerable to necrosis due to increased levels of mPTP related proteins. 
Increased susceptibility to necrosis instead of apoptosis in fatty hepatocytes is expected to render 
fatty livers prone to necrosis-induced inflammation. Once inflammation occurs, the prognosis of 
NAFLD patients declines [1, 4]. Our study provides data regarding the mechanism underlying 
the increased vulnerability of fatty liver to necrosis and introduces potential targets for therapy 
to prevent necrosis in fatty livers namely by inhibiting mPTP in hepatocytes. Such an apporoach 
would protect fatty livers against inflammation and exacerbation of liver damage.
In summary, our study demonstrates that fatty hepatocytes are more susceptible to necrosis 
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Background and Aim: Angiotensin II (AT-II) is a profibrotic compound that acts via membrane-
bound receptors (AT-1R/AT-2R) and thereby activates hepatic stellate cells (HSCs). AT-II  receptor 
antagonists are thus considered in the treatment of liver fibrosis. However, multiple case reports 
suggest that AT-1R receptor antagonists may induce liver injury. Therefore, we investigated the 
effect of AT-II and its receptors on cytokine-, oxidative stress- and bile salt-induced cell death in 
hepatocytes.
Methods: Primary rat hepatocytes were exposed to TNFa/Actinomycin D, the ROS-generating 
agent menadione or the bile salt, GCDCA, to induce apoptosis. AT-II (100 nmol/L) was added 
10 minutes prior to the cell death-inducing agent. AT-1R antagonists (Sartans) and the AT-2R 
antagonist PD123319 were used at 1 µmol/L. Apoptosis (caspase-3 activity, acridine orange 
staining) and necrosis (Sytox green staining) were quantified.
Results: Expression of CHOP (marker for ER stress)  and AT-II receptor mRNAs were quantified 
by Q-PCR. AT-II dose-dependently reduced GCDCA-induced apoptosis of hepatocytes (-50%, 
p< 0.05) without inducing necrosis. AT-II did not suppress TNF/Act-D and menadione-induced 
apoptosis. Only the AT-1R antagonists abolished the protective effect of AT-II against GCDCA-
induced apoptosis. AT-II increased phosphorylation of ERK and a significant reversal of the 
protective effect of AT-II was observed when signaling kinases, including ERK, were inhibited. 
Moreover, AT-II prevented the GCDCA-induced expression of CHOP.
Conclusion: Angiotensin II protects hepatocytes from bile salt-induced apoptosis through a 
combined activation of PI3-kinase, MAPKs, PKC pathways and inhibition of bile salt-induced 
ER stress. Our results provide an explanation for the observed hepatotoxicity of sartans in some 




Angiotensin II (AT-II) is the effector peptide of the renin angiotensin system (RAS), which plays 
a crucial role in regulating blood pressure. In addition to the systemic generation of AT-II in the 
circulation by RAS, AT-II is also produced locally in various organs, including kidney, vessels, heart, 
adrenal gland, brain and liver, as a result of  a process commonly termed “tissue” renin-angiotensin 
system (RAS) (5). Tissue RAS plays an important role in maintaining cardiovascular homeostasis, 
but also in mediating diverse physiologic functions such as cell growth, cell differentiation and 
apoptosis (38). The effects of angiotensin II on organs are mediated via the AT-II type 1 and type 2 
receptors (AT-1R and AT-2R) (38). It has been shown that components of the RAS are present and 
activated in chronic liver diseases (10, 36).
Chronic liver diseases, including cholestatic liver disease, are characterized by loss of functional 
liver mass due to hepatocyte cell death and the development of  liver fibrosis that may progress 
to end-stage liver cirrhosis. Hepatic RAS is suggested to play an important role in liver fibrosis 
(50). Most, if not all, of the key components of RAS that lead to the generation of AT-II are 
present in the liver (28, 50) and are induced and/or redistributed in liver injury (10, 23, 36, 37). 
AT-II levels are increased both in plasma and in liver tissue in rat models of liver disease, as well 
as in cirrhotic patients (4, 36). It was shown that AT-II, generated by systemic RAS and/or tissue 
RAS, plays a role in the progression of liver fibrosis through activation and proliferation of hepatic 
stellate cells (HSCs) (8, 9). Moreover, activated hepatic stellate cells express RAS-components 
and synthesize AT-II themselves (10). HSC-derived AT-II, as well as systemic AT-II, can exert 
paracrine and endocrine actions on hepatocytes, which express high levels of AT-1R (10). Recent 
studies revealed that blocking the RAS pathway with either AT-1R blockers (ARB) or angiotensin 
converting enzyme inhibitors (ACEi) attenuates the progression of liver fibrosis in animal models 
of chronic liver diseases (16, 20, 50). Consequently, blockade of AT-II signal transduction has been 
suggested to be a beneficial therapy in patients with chronic liver diseases. Until now, only a small 
number of studies examining the effect of RAS inhibition on fibrosis in human liver diseases have 
been reported and there are no results from large randomized trials (reviewed in (50)). Notably, a 
recent cohort study in chronic hepatitis C patients with advanced liver fibrosis showed that ACEi/
ARB therapy does not prevent the progression of hepatic fibrosis (1). On the other hand, there are 
multiple (case) reports ARBs and ACEis may induce  hepatocellular injury and/or cholestasis (2, 3, 
7, 13, 18, 26, 33, 41, 45, 48). Losartan and candesartan were found to induce hepatocellular injury 
in hypertensive patients with normal liver function tests prior to the start of the therapy (3, 7, 13, 
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33, 45, 48). Irbesartan therapy leads to hepatocyte cholestasis and degeneration in hypertensive 
patients (2, 18) and valsartan has been reported to induce lobular necrosis and inflammation in the 
liver (26, 41). There are also numerous reports of the potential hepatotoxicity of ACE inhibitors 
(reviewed in(17)). Thus, inhibition of the RAS system in fibrotic liver disease may have negative 
effects on liver function and hepatocyte viability in particular. 
Liver injury may be caused by (a combination of ) inflammation, oxidative stress and increased 
bile salt levels, leading to apoptosis and/or necrosis of hepatocytes. Therefore, we studied the 
effect of AT-II on cytokine-, ROS- and bile salt-induced apoptosis and necrosis in primary rat 
hepatocytes. AT-II specifically attenuated bile salt-induced apoptosis, but not cytokine- or oxidative 
stress-induced apoptosis. Subsequently, we analyzed the involvement of the AT-II receptors, protein 
kinase signaling pathways and ER stress in bile acid-induced apoptosis in detail.
Materials and Methods
Animals 
Specified pathogen-free male Wistar rats (220-250 g) were purchased from Charles River 
Laboratories Inc. (Wilmington, MA, USA). Animals were kept under standard laboratory conditions 
with free access to standard laboratory chow and water. All the experiments were performed in 
accordance with the guidelines of the local Committee for Care and Use of laboratory animals.
Rat hepatocyte isolation 
Hepatocytes were isolated and cultured in multiwell plates (Greiner bio-one) in William’s E 
medium in a humidified incubator at 37 ºC and 5% CO2 as described before (49). 
Experimental design
Experiments were started after the attachment period of 4 hours. Monolayers of cultured primary 
hepatocytes were treated with angiotensin II (Sigma-Aldrich) at the indicated concentrations 
starting 10 minutes prior to the exposure to 50 µmol/L GCDCA (Sigma-Aldrich) for 4 hours or to 
100 µmol/L of TLCS (Sigma-Aldrich) for 6 hours or to 20 ng/ml recombinant murine Tnfα (R&D 
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Systems, Abingdon, United Kingdom) for 16 hours or to 50 µmol/L menadione (superoxide anion 
donor; Sigma-Aldrich) for 9 hours unless stated otherwise. Signal transduction pathways were 
inhibited using 10 µmol/L of the ERK1/2 inhibitor U0126 ( Promega, Madison, USA), 10 µmol/L 
of the p38 inhibitor SB 203580 (Calbiochem), 50 µmol/L of the PI3 kinase inhibitor LY 294002 
(Calbiochem), 1 µmol/L of the protein kinase-C inhibitors Calphostin-C and Bisindolylmaleimide 
I (BSM-I)  (Calbiochem), and 200 ng/ml of the transcriptional inhibitor actinomycin-D (Roche 
Diagnostics, Almere, the Netherlands). Angiotensin II type 1 receptor was inhibited by the receptor 
antagonists Losartan (Merck), Valsartan (Novartis Pharma), Irbesartan (Bristol-Myers-Suibb) and 
Candesartan (Astra Zeneca, Zoetermeer, the Netherlands) all used at 1 µmol/L. Angiotensin II type 
2 receptor was inhibited by 1 µmol/L of the selective antagonist PD 123319 (Sigma-Aldrich). All 
inhibitors and receptor antagonists were added to the cultured hepatocytes 30 minutes prior to the 
apoptotic stimuli unless stated otherwise. Every experimental condition was performed in triplicate 
wells and each experiment was repeated at least three times using hepatocytes from different rats. 
Cells were harvested at the indicated time points as described previously (44). 
Apoptosis and necrosis assays 
Caspase-3 activity was measured as described previously (44). The arbitrary fluorescence unit 
(AFU) was corrected for the amount of protein. Protein concentration was determined using the 
Bio-Rad protein assay kit. Sytox green (Invitrogen) and acridine orange (Sigma-Aldrich) were used 
to visualize necrotic and apoptotic cell death, respectively, as described before (54). 
Quantitative PCR
RNA isolation, reverse transcription PCR and quantitative PCR (qPCR) were performed as 
described previously (54). Each sample was analyzed in duplicate. 18S mRNA levels were used as 
endogenous control. Primers and probes are listed inTable 1.
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Western blot analysis was performed as described previously (54). Expression of selected protein 
was assessed using monoclonal mouse antibody against phosphorylated ERK1/2 (p44/42) at a 
dilution of 1:1000. Blots were subsequently stripped using 0.1% SDS/0.1% Tween – PBS at 65ºC 
for 30 minutes and incubated with 1:4000 diluted monoclonal mouse antibody against GAPDH 
(Calbiochem, La Jolla, CA. USA). Horse radish-peroxidase conjugated rabbit anti-mouse Ig 
(DAKO, Denmark) was used every time as a secondary antibody at a dilution of 1:2000.
Statistical analysis 
Results are presented as the mean of at least 3 independent experiments ± SD. A Student t-test 
or two way ANOVA test was used to determine the significance of differences between experimental 
groups. A P-value of less than 0.05 (P<0.05) was considered statistically significant.
Results
Angiotensin II inhibits bile acid-induced caspase-3 activity and apoptotic nuclear morphology
 
TNFα (20 ng/ml)/ActD (200 ng/ml), menadione (at 50 µM) and GCDCA (at 50 µM) induce 
caspase-3 activity in primary rat hepatocytes peaking after 16 hours-, 9 h- and 4h-exposure, 







Figure1: Angiotensin II (Ag II) inhibits glycochenodeoxycholic acid (GCDCA)-induced caspase-3 activity and 
nuclear fragmentation in rat hepatocytes but does not protect rat hepatocytes against TNFα- and menadione-
induced apoptosis. (A) Caspase-3 activity in rat hepatocytes treated with 20 ng/ml of TNFα and 200 ng/ ml of 
transcriptional inhibitor actinomycin-D for 16 hours in the presence and absence of 100 nmol/L Ag II. (B) Caspase-3 
activity in rat hepatocytes treated with 50 µmol/L of menadione for 9 hours in the presence and absence of 100 nmol/L 
Ag II. (C) Primary rat hepatocytes were treated for 4 hours with 50 µmol/L of GCDCA, 100 nmol/L of Ag II or a 
combination of both. Ag II was added 10 min prior to the addition of GCDCA. * P < 0.05 for GCDCA +Ag II vs. 
GCDCA alone. (D) Hepatocytes were treated with different concentrations of Ag II 10 min prior to the addition of 50 
µmol/L of GCDCA for 4 hours. (E) Ag II (100nmol/L) significantly inhibits GCDCA-induced caspase-3 activation. * 
P < 0.05 for GCDCA (50, 100, 200 µM) + Ag II vs GCDCA (50, 100, 200µM) alone. (F) Acridine orange staining. 
Treatment with 50 µmol/L of GCDCA induces nuclear condensation and fragmentation which is blocked with 100 
nmol/L Ag II at 15 hours-time point. (G) Ag II inhibits tauro-lithocholic acid-3 sulfate (TLCS)-induced caspase-3 
activity. Hepatocytes were treated for 6 hours with 100 µmol/L of TLCS, 100 nmol/L of Ag II or a combination of 
both. Cells were treated with Ag II 10 min prior to the addition of TLCS. * P < 0.05 for TLCS +Ag II vs. TLCS alone.
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The effect of AT-II on cytokine-, oxidative stress- and bile acid-induced caspase-3 activity in 
primary hepatocytes was investigated at these time points. Exposure of primary rat hepatocytes 
to AT-II (100 nmol/L) alone did not induce caspase-3 activity ( Figure1A), nor did it reduce the 
caspase-3 activity in TNFα/ActD-treated or menadione-treated rat hepatocytes (Figure1A and 
B). In contrast, AT-II significantly inhibited the GCDCA-induced caspase-3 activity (Figure1C; 
-50% approximately, p<0.05), which was concentration-dependent (Figure1D). In all subsequent 
experiments a concentration of 10-7 mol/L (100 nmol/L) of AT-II was used. AT-II attenuated the 
GCDCA-induced caspase-3 activity at different apoptosis-inducing concentrations of GCDCA 
(50-200 µM; Figure1E). At higher GCDCA concentrations the primary mode of cell death shifts 
to necrosis (54), which is not prevented by AT-II (Figure1E). AT-II may delay, rather than prevent 
GCDCA-induced apoptosis in rat hepatocytes. To establish true protection by AT-II, GCDCA-
treated hepatocytes were stained with acridine orange after 6 and 15 h exposure with and without 
AT-II. Nuclear fragmentation and condensation, markers for end-stage apoptosis, became detectable 
6 hours after the addition of GCDCA and increased over time (shown for 15 h treatment;Figure1F). 
Nuclear fragmentation and condensation were reversed to control levels when GCDCA-exposed 
hepatocytes (after 15h) were co-treated with AT-II (Figure1F). Importantly, AT-II did not induce 
necrosis in hepatocytes, nor did it increase the number of necrotic cells after exposure to GCDCA 
(data are not shown).
To determine whether AT-II is also protective towards cytotoxic effects of other bile salts, the 
effect on tauro-lithocholic acid-3 sulfate (TLCS)-induced caspase-3 activity was studied. Similar as 
for GCDCA, AT-II attenuated TLCS-induced caspase-3 activity in primary rat hepatocytes with 
approximately 50% (Figure1G).
Remarkably, no protective effect of AT-II was detected in bile salt (GCDCA)- and cytokine-
induced apoptosis in HepG2-rNtcp cells (Suppl. Fig.1 A and B), which suggests that the AT-II-
stimulated signaling pathways are absent in these cells.
The protective effect of angiotensin II is mediated via the angiotensin receptor type -1 
AT-II signaling depends on the presence of AT-II receptors in cellular membranes. AT-1R but 
not AT-2R has previously been shown to be expressed in hepatocytes (36). We confirmed significant 
mRNA expression for AT-1R in rat hepatocytes, comparable to those in activated rat hepatic stellate 
cells, used as positive control (data are not shown). The role of AT-1R and AT-2R in the protective 
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effect of AT-II against GCDCA-induced apoptosis was investigated using specific antagonists of 
AT-1R (various sartans) or AT-2R (PD123319). 
A B
Figure2: The protective effect of angiotensin II (Ag II) against glycochenodeoxycholic acid (GCDCA)-induced 
apoptosis is mediated via the angiotensin II type-1 receptor (AT-1R). (A) Hepatocytes were treated with 1 µmol/L 
of selective AT-1R antagonists (Losartan, Valsartan, Irbesartan and Candesartan) 30 minutes prior to the addition of 
GCDCA (50 µM) + Ag II (100 nmol/L). * P < 0.05 for GCDCA+ Ag II+ AT-1 antagonists vs. GCDCA + Ag II. (B) 
Hepatocytes were treated with 1 µmol/L of the selective AT-2 antagonist (PD 123319) 30 minutes prior to the addition 
of GCDCA (50 µM) + Ag II (100nmol/L).
The protective effect of AT-II against GCDCA-induced apoptosis was completely abolished in 
the presence of the various sartans tested (losartan, valsartan, irbesartan and candesartan), strongly 
indicating that the protective effect of AT-II is mediated through AT-1R (Figure2A). In contrast, 
inhibition of AT-2R with PD123319 did not affect the protective action of AT-II against GCDCA-
induced apoptosis in hepatocytes (Figure2B). 
Time window of anti-apoptotic action of angiotensin II
We next investigated whether AT-II needs to be present during the GCDCA treatment to protect 
hepatocytes against apoptosis. Hepatocytes were pre-incubated with AT-II for 10 minutes. Medium 
was removed and cells washed and then exposed to GCDCA in fresh medium with or without AT-
II for 4 hours. Caspase-3 activity was inhibited in the presence of AT-II and the protective effect 
of AT-II persisted in hepatocytes exposed to GCDCA in fresh medium without AT-II (Figure3A). 
Furthermore, addition of AT-II up to 30 minutes after the start of the GCDCA treatment still 
exerted maximum protection against GCDCA-induced apoptosis (Figure3B). No protective effect 
of AT-II was detected when AT-II was added at later time points (1-3 h after GCDCA treatment; 
Figure3B). These data show that the anti-apoptotic actions of AT-II are rapidly induced and suggest 
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the involvement of protein kinase signal transduction pathways in the protective actions of AT-II 
against GCDCA-induced apoptosis.
A B
Figure3: The protective effects of angiotensin II (Ag II ) are induced rapidly. (A) Hepatocytes were pre-incubated 
with 100 nmol/L of Ag II for 10 minutes after which cells were washed and exposed to 50 µmol/L of GCDCA alone 
(+ / - Ag II) or with simultaneous addition of Ag II ( + / + Ag II). * P < 0.05 for GCDCA + Ag II (+ / -) and GCDCA 
+ Ag II (+ / +) vs. GCDCA 50 µM. (B) hepatocytes were stimulated with 50 µmol/L GCDCA for 4 hours (GCDCA 
50). Ag II (100 nmol/L) was added 10 minutes prior to (-10 min), simultaneous with (0 min) or 30 minutes (+30 min), 
1 hour (+1 hr), 2 hours (+2 hrs), 3 hours (+3hrs) after the addition of GCDCA.* P <0.05 for -10 min of Ag II, 0 min 
of Ag II, +30 min of Ag II vs GCDCA alone.
Anti-apoptotic action of angiotensin II depends on the combined activation of ERK1/2, p38 MAP 
Kinase, PI3kinase and protein kinase C 
To investigate whether specific kinase pathways are involved in the anti-apoptotic effects of AT-
II, GCDCA-exposed rat hepatocytes were co-treated with inhibitors of MAPK, PI3K and PKC. 
These inhibitors alone do not induce caspase-3 activity in rat hepatocytes, nor do they enhance 
the GCDCA-induced caspase-3 activation. (Figure4A). The protective effect of AT-II against 
GCDCA-induced apoptosis was significantly, albeit partially, abolished by inhibition of ERK1/2, 
p38 MAP kinases and PI3 kinase pathways (Figure4A). Additive effects were observed when 
ERK1/2 and p38 MAK kinase were inhibited simultaneously. In support, AT-II increased the levels 
of phosphorylated ERK1/2 MAPK in control hepatocytes as well as in the presence of GCDCA, 
which was abolished by the AT-1R antagonist candesartan (Figure4B). In the presence of PKC 
inhibitors, the protective effect of angiotensin II against GCDCA-induced caspase-3 activation was 





Figure4: The protective effect of angiotensin II (Ag II) against glycochenodeoxycholic acid (GCDCA)-induced 
apoptosis is dependent on the activation of p38 MAP kinase, ERK1/2 MAPK, PI3K pathway and PKC pathway. 
(A) Caspase-3 activity in rat hepatocytes treated with 50 µmol/L of GCDCA in the presence and absence of 100 
nmol/L Ag II and with or without the inhibitors of ERK MAPK (10 µmol/L of U0126; U0), p38 MAPK (10 µmol/L 
of SB 203580; SB), PI3K (50 µmol/L of LY 294002; LY) and PKC (1 µmol/L of Calph. C or BSM-I). *P < 0.05 
for GCDCA + Ag II+ LY vs. GCDCA+ Ag II , for GCDCA + Ag II+ SB vs. GCDCA+ Ag II, for GCDCA+ Ag II + 
U0 vs. GCDCA+ Ag II and for GCDCA+ Ag II + U0+LY vs. GCDCA+ Ag II, for GCDCA+ Ag II + Calph.C vs. 
GCDCA + Ag II and for GCDCA + Ag II + BSM-I vs. GCDCA + Ag II. (B) Western blot analysis for phosphorylated 
ERK1/2 MAPK in cell lysates of GCDCA-exposed hepatocytes (10 min) with and without Ag II. ERK1/2 MAPK 
phosphorylation was inhibited in the presence of AT-1 antagonist (1 µmol/L of candesartan).
Angiotensin II attenuates GCDCA-induced endoplasmic reticulum stress
Besides kinase signaling pathways, hydrophobic bile acids, such as GCDCA, may also induce 
apoptosis by increasing ER stress and induction of the unfolded protein response via transcription 
factors like CHOP (12, 47). Induction of CHOP is a sensitive marker for ER stress and CHOP-
knockout mice are protected against cholestasis-induced hepatocyte apoptosis (25, 46). Indeed, 
GCDCA treatment of rat hepatocytes lead to a transient increase in CHOP mRNA levels that 
peaked at 2 hours after GCDCA treatment, after which they gradually decrease to control levels 
after 4-8 hours (Figure5). AT-II prevented the GCDCA-induced expression of CHOP in rat 
hepatocytes at all different time points tested, while it did not exert any effect on CHOP levels in 
control hepatocytes (Figure5). 
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Figure5: Angiotensin II (Ag II) attenuates GCDCA-induced ER stress in rat hepatocytes. QPCR analysis of Chop 
mRNA (ER stress marker) in rat hepatocytes treated with 50 µmol/L GCDCA at several time points  with or without 
100 nmol/L of Ag II using cDNA of hepatocytes.  mRNA expression level is presented relative to control. * P < 0.05 
for GCDCA +Ag II vs. GCDCA alone.
 
Discussion 
In this study, we report that angiotensin II (AT-II) protects primary rat hepatocytes specifically 
against bile salt-induced apoptosis. We demonstrate that the protective effects of AT-II are mediated 
via AT-1R signal transduction and activation of ERK, p38 MAPK, PI3K and PKC signaling 
pathways. In addition, we show that AT-II treatment reduces the bile salt-induced expression of 
CHOP, an ER stress-induced effector peptide, in primary rat hepatocytes. These findings suggest 
that inhibition of systemic and/or tissue RAS pathway in (cholestatic) liver fibrosis should be 
monitored carefully as it blocks the hepatoprotective action of AT-II on liver parenchymal cells. 
AT-II antagonists (ACEi and/or ARB) are considered as therapeutics for fibrotic liver diseases 
as they prevent HSC activation and proliferation (50). However, the effect of AT-II antagonist 
therapy on hepatocytes has not previously been studied. Hepatocytes are the most abundant cell 
type in the liver. They express several components of RAS including AT-1R and exhibit numerous 
responses to AT-II, including the activation of gene transcription (14, 31, 36, 53). Therefore, it is 
likely that AT-II harbors specific roles in (diseased) hepatocytes and AT-II antagonist therapy may 
lead to hepatotoxicity. Indeed, ACEi- and ARB-induced hepatocellular injury and liver damage has 
been reported previously (3, 7, 13, 33, 45, 48). Losartan, Candesartan and Irbesartan were found 
to induce hepatocellular injury, hepatocyte cholestasis and degeneration in patients with essential 
hypertension and normal liver function tests prior to the start of the therapy (2, 18). Valsartan 
was found to induce lobular necrosis and inflammation in the liver (26, 41) and ACE inhibitors 
were reported to cause severe hepatic necrosis or drug-induced hepatotoxicity (reviewed in (17)). 
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Several mechanisms have been suggested for ARB-induced hepatotoxicity and cholestasis such as 
metabolic idiosyncrasy and immune mechanisms. However, the hypothesis that angiotensin II has 
hepatoprotective effects and ARBs sensitize hepatocytes to toxic stimuli has not been investigated 
before. In the present study, we have used several apoptotic stimuli (cytokines, ROS and bile 
salts) that are increased in chronic liver diseases and lead to hepatocyte injury, to investigate the 
effect of AT-II on hepatocytes. Our data strongly demonstrate that AT-II has an AT-1R-mediated 
hepatoprotective effect on hepatocytes which are prevented by several ARBs. It has previously been 
observed that hepatocytes express AT-1R and the up-regulation of this receptor in cholestatic liver 
injury has been reported, whereas the AT-2R is suggested to be absent or very low expressed in 
hepatocytes (10, 43). Our data confirm that AT-2R-mediated signaling does not play a major role 
in hepatocytes cell death or survival.
Interestingly, AT-II protects hepatocytes against bile salt-induced apoptosis, but not against 
TNFα- or menadione-induced apoptosis. This could be due to the induction of different apoptotic 
signaling pathways in response to these apoptotic stimuli. Menadione induces apoptosis in hepatocytes 
via production of reactive oxygen species (ROS) leading to oxidative stress in hepatocytes (15). 
Previously, we have shown that ROS are not essential for bile salt-induced cell death in hepatocytes 
and anti-oxidant therapy does not protect hepatocytes against bile salt-induced apoptosis (54), 
indicating different mechanisms for bile acid and ROS-induced hepatocyte apoptosis. TNFα-
induced apoptosis in hepatocytes is shown to be mediated via death-receptor-dependent signaling 
(TNF receptor type 1, TNF-R1), leading to recruitment of Fas associated death domain (FADD), 
activation of caspase-8 and pro-apoptotic proteins, Bak and Bid (43, 44). In contrast, it has been 
shown that bile salt-induced caspase-8 activation is FADD-independent and inhibition of caspase-8 
has no effect on bile salt- induced caspase-3 activation (43). This may explain why AT-II-induced 
signaling pathways cannot counteract the menadione- and TNFα-induced apoptotic signaling, 
whereas they do protect hepatocytes against bile salt-induced apoptosis.
We provide evidence that the protective effects of AT-II are mediated via a combined activation 
of protein kinase signal transduction pathways, as we observed partial effects of specific kinase 
inhibitors, reversing the protective effects of AT-II. In accordance with our data, previous studies 
have also indicated that AT-II stimulates activation of ERK, PI3K, p38 MAPK and PKC (11, 19, 
32, 51, 52, 57). It has been observed that taurine-conjugated UDCA (TUDCA)-induced activation 
of the ERK, PI3K and p38 MAPK protects primary rat hepatocytes against bile salt-induced 
apoptosis (42). Thus, it is likely that AT-II mediated activation of these protein kinases aid to the 
survival of cholestatic hepatocytes. PKC signaling cascade is suggested to play an important role 
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in AT-II related pathophysiology (19, 58). Interestingly, PKC-alpha has been reported to inhibit 
hepatic apoptosis through an increase of anti-apoptotic Bcl-2 family proteins such as Bcl-XL (21, 
24). Induction of the expression of anti-apoptotic Bcl-XL as a consequence of PKC activation by 
AT-II may be part of the hepatoprotective effect of AT-II in cholestatic hepatocytes. In addition, 
AT-II attenuated the bile salt-induced CHOP expression. CHOP is one of the most sensitive 
markers for ER stress that activates the ER stress-induced apoptotic pathway (35). Overexpression 
or microinjection of CHOP protein have been reported to lead to cell cycle arrest and/or apoptosis 
(6, 29). CHOP can induce the expression of the proapoptotic BH3-only protein Bim and the 
cell surface death receptor TRAIL receptor 2 (also known as death-receptor 5, DR5) and inhibit 
transcription of the anti-apoptotic protein Bcl-2 (30, 40, 56). In contrast, CHOP disruption in 
cells leads to reduced apoptosis in response to ER-stress (34). Indeed, CHOP deficiency reduces 
cholestasis-induced hepatocyte apoptosis (46). Activation of ERK 1/2 MAP kinase and PI3K/Akt 
pathway were found to attenuate the ER stress-induced apoptosis and reduce CHOP expression, 
leading to cell survival (22, 39, 59). Furthermore, activation of PKC signaling pathway has been 
suggested to inhibit the ER stress-induced caspase-12 and caspase-3 activation and therefore inhibit 
apoptosis (27). Interestingly, inhibition of the ER-stress response by TUDCA is a hepatoprotective 
mechanism in liver disease (55). Our data suggest that activation of these protein kinases in AT-II-
treated hepatocytes inhibits the ER stress response, leading to hepatocyte survival.
The hepatoprotective effect of AT-II against bile salt-induced apoptosis has great clinical relevance 
in AT-II antagonist therapy of patients with cholestatic liver fibrosis. As patients with chronic liver 
diseases usually visit the clinicians when their disease is already advanced and the therapy has to start 
in already diseased livers containing diseased (e.g. cholestatic) hepatocytes, it is important to clarify 
the response of hepatocytes to therapy (AT-II vs ARBs). Our data suggest that despite the beneficial 
effects of ARBs on liver fibrosis, they may hypersensitize the adjacent hepatocytes to certain toxic 
stimuli such as bile salts, leading to further loss of functional hepatocytes. Therefore, liver function 
should be closely monitored during the AT-II antagonist therapy of cholestatic liver fibrosis, 
especially in the early stages of cholestatic liver disease (when there is still considerable amount of 
functional hepatocytes). In addition, targeting AT-II antagonists specifically to hepatic stellate cells 
can be a good solution in order to prevent hepatocyte loss during the treatment of liver fibrosis. 
Combined UDCA/ARBs therapy could serve as an alternative option to protect hepatocytes while 
treating liver fibrosis in cholestatic liver diseases, as UDCA has similar hepatoprotective effects as 
were observed for AT-II in our study and UDCA is already used in clinic for patients with chronic 
cholestatic diseases. In summary, we show that AT-II protects primary rat hepatocytes against bile 
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salt-induced apoptosis via the AT-1R-mediated activation of the signaling protein kinases and 




Suppl. Fig.1: Angiotensin II (Ag II) has no protective effect in bile salt- and TNFα/ActD-induced apoptosis 
in HepG2-rNtcp cells. The human hepatoma cell line HepG2 stably expressing the bile salt importer rNtcp, 
were cultured. (A) Cells were incubated with 200 µmol/L of GCDCA for 4 hours in the presence and absence of 100 
nmol/L of Ag II. Cells were harvested hypotonic cell lysis buffer and caspase-3 activity was measured. (B) Cells were 
incubated with 20 ng/ml of human recombinant TNFα for 16 hours in the presence and absence of 100 nmol/L of Ag 
II. 200 ng/ ml of transcriptional inhibitor actinomycin-D  was added to the cells prior to the addition of TNFα. Cells 
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Chapter 5
Pertussis toxin, an inhibitor of Gαi proteins, inhibits bile acid- and cytokine-





Dept. Gastroenterology and Hepatology, University of Groningen, University Medical Center 





Background and Aim: Excessive hepatocyte apoptosis is a common event in acute and chronic liver 
diseases leading to loss of functional liver tissue. Approaches to prevent apoptosis have therefore 
high potential for the treatment of liver disease. G-protein coupled receptors (GPCR) play crucial 
roles in cell fate (proliferation, cell death) and act through heterotrimeric G-proteins. GαiPCRs 
have been shown to regulate lipoapoptosis in hepatocytes, but their role in inflammation- or bile 
acid-induced apoptosis is unknown. Here, we analyzed the effect of inhibiting GαiPCRs function, 
using pertussis toxin (PT), on bile acid- and cytokine-induced apoptosis in hepatocytes. 
Methods: Primary rat hepatocytes or HepG2-rNtcp cells (human hepatocellular carcinoma cells) 
were exposed to glycochenodeoxycholic acid (GCDCA) or tumor necrosis factor-α (TNFα)/
actinomycin D (ActD). PT (50-200 nmol/L) was added 30 minutes prior to the apoptotic stimulus. 
Apoptosis (caspase-3 activity, acridine orange staining) and necrosis (sytox green staining) were 
assessed. 
Results: PT significantly reduced GCDCA- and TNFα/ActD-induced apoptosis in rat hepatocytes 
(-60%, p< 0.05) in a dose-dependent manner (with no shift to necrosis), but not in HepG2-rNtcp 
cells. The protective effect of pertussis toxin was independent of the activation of selected cell 
survival signal transduction pathways, including ERK, p38 MAPK, PI3K and PKC pathways, as 
specific protein kinase inhibitors did not reverse the protective effects of pertussis toxin in GCDCA-
exposed hepatocytes. 
Conclusion: Pertussis toxin, an inhibitor of GαiPCRs, protects hepatocytes, but not hepatocellular 
carcinoma cells, against bile acid- and cytokine-induced apoptosis and has therapeutic potential as 




In chronic and acute liver diseases, the liver is exposed to increased levels of cytokines, 
reactive oxygen species and  bile acids, all of which independently can lead to loss of functional 
liver mass due to hepatocyte cell death. Concomitantly, hepatic stellate cells become activated, 
start proliferating and produce excessive amounts of extracellular matrix proteins leading to liver 
fibrosis, which may progress to end-stage liver disease [1]. Hepatocyte cell death can occur via 
apoptosis, necrosis or a combination of these different types of cell death [2]. Apoptosis is an 
energy-dependent process, resulting in the formation of apoptotic bodies. Apoptotic bodies are 
cleared by surrounding phagocytosing cells that minimize inflammation. In contrast, uncontrolled 
apoptosis and (secondary) necrosis trigger inflammation in the liver [3, 4]. Despite worldwide 
efforts to establish therapeutic strategies for liver injury, end-stage liver disease remains a high 
burden for public health due to the lack of effective treatments. Excessive hepatocyte apoptosis 
is often observed in liver disease and, as this is a highly controlled cellular mechanism, drugs and 
therapeutic strategies to prevent hepatocyte apoptosis may help to maintain sufficient liver mass 
and function [1].
Recently, G-protein coupled receptors (GPCRs) have been suggested as new drug targets to 
treat cardiac diseases and cancer, as GPCRs play crucial roles in the regulation of cell proliferation, 
angiogenesis, cell survival and apoptosis [5, 6]. GPCRs are the largest family of membrane proteins 
and are essential nodes of communication between the internal and external environment of the 
cells. Over 300 GPCRs have been reported in human and rodents [7]. Upon activation by agonists, 
GPCRs activate heterotrimeric G-proteins (Gαβγ). These subunits subsequently activate second 
messengers (e.g. cAMP, Ca2+ and protein kinases), submitting the GPCR induced-signal to the 
intracellular targets. Heterotrimeric G-proteins are divided into 4 families (i.e., Gαs, Gαi, Gαq/11 
and Gα12/13) based on the Gα subunit sequence identity and signaling activity [8].
A number of bacterial endotoxins are suggested as excellent tools to study the function of GPCRs, 
as they covalently modify the α-subunit of G-proteins, altering their function (reviewed in [8]). 
Pertussis toxin (PT), an exotoxin produced by Bordetella pertussis (the causative agent of whooping 
cough), is shown to be a mono-ADP-ribosyltransferase that covalently modifies the α-subunit of 
Gi proteins. This ribosylation is irreversible and prevents the G-proteins from interacting with G 
protein-coupled receptors on the cell membrane, thus interfering with intracellular communication 
[9-11]. As a result, the function of effector proteins, such as adenylyl cyclase, ERK/MAPK and Ca2+ 
channels is changed and modulates cell proliferation, survival and angiogenesis [8]. Interestingly, 
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GPCRs antagonists have shown excellent therapeutic benefits in clinical trials in controlling tumor 
growth and apoptosis [6]. Therefore, GPCR-based drugs may also show therapeutic benefits in 
regulation of apoptosis and/or survival in liver diseases.
GPCRs are present in hepatocytes and play an important role in the regulation of several 
hepatocyte functions, including gluconeogenesis and lipid storage [12-15]. In addition, 
lysophosphatidylcholine has been shown to act via a GαiPCR-dependent mechanism in lipoapoptosis 
of hepatocytes [14]. Whether PT-sensitive GPCRs also play a role in other apoptotic signals, like 
bile acid- or cytokine-induced apoptosis, is not known. In this study, we have investigated the 
effect of PT-mediated inhibition of GPCRs in models of TNFα- and GCDCA-induced apoptosis 
in primary rat hepatocytes. Our data provide new information about the function of PT-sensitive 
GPCRs during liver injury and suggest new targets for treatment of liver diseases.
Materials and Methods
Animals 
Specified pathogen-free male Wistar rats (220-250 g) were purchased from Charles River 
Laboratories Inc. (Wilmington, MA, USA). Animals were kept under standard laboratory conditions 
with free access to standard laboratory chow and water. All the experiments were performed in 
accordance with the guidelines of the local Committee for Care and Use of laboratory animals.
Rat hepatocyte isolation 
Hepatocytes were isolated and cultured in multiwell plates (Greiner bio-one) in William’s E 
medium in a humidified incubator at 37 ºC and 5% CO2 as described before [16]. 
Experimental design
Experiments were started after the attachment period of 4 hours. In order to inhibit the α-subunit 
of G-proteins, monolayers of cultured primary hepatocytes were treated with pertussis toxin 
(Calbiochem, VWR International, Amsterdam, the Netherlands) at the indicated concentrations 
starting 30 minutes prior to the exposure to 50 µmol/L GCDCA (Sigma-Aldrich) for 4 hours or 20 
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ng/ml recombinant murine TNFα (R&D Systems, Abingdon, United Kingdom) for the indicated 
time period, unless stated otherwise. Signal transduction pathways were inhibited using 10 µmol/L 
of the ERK1/2 inhibitor U0126 ( Promega, Madison, USA), 10 µmol/L of the p38 inhibitor SB 
203580 (Calbiochem), 50 µmol/L of the PI3 kinase inhibitor LY 294002 (Calbiochem), 1 µmol/L 
of the protein kinase-C inhibitors Calphostin-C and Bisindolylmaleimide I (BSM-I)  (Calbiochem), 
and 200 ng/ml of the transcriptional inhibitor actinomycin-D (Roche Diagnostics, Almere, the 
Netherlands). All inhibitors and receptor antagonists were added to the cultured hepatocytes 30 
minutes prior to the apoptotic stimuli unless stated otherwise. Each experimental condition was 
performed in triplicate. Each experiment was repeated at least three times using hepatocytes from 
different rats. Cells were harvested at the indicated time points as described previously [16]. 
HepG2-rNtcp cell experiments
The human hepatoma cell line HepG2 stably expressing the bile acid importer rNtcp, was 
cultured as described before [17]. Cells were incubated with GCDCA (200 µmol/L) or human 
recombinant TNFα (20 ng/ml) for the indicated time points. The transcriptional inhibitor 
actinomycin-D (Roche Diagnostics, Almere, the Netherlands) was added to the cells prior to the 
addition of TNFα. Cells were harvested at the indicated time points in hypotonic cell lysis buffer 
[16].
Apoptosis and necrosis assays 
Caspase-3 activity was measured as described previously [16]. The arbitrary fluorescence unit 
(AFU) was corrected for the amount of protein. Protein concentration was determined using the 
Bio-Rad protein assay kit. Sytox green (Invitrogen) and acridine orange (Sigma-Aldrich) were used 
to visualize necrotic and apoptotic cell death, respectively, as described before [18]. 
Statistical analysis 
Results are presented as the mean of at least 3 independent experiments ± SD. A two way 
ANOVA test was used to determine the significance of differences between experimental groups. A 




Pertussis toxin inhibits bile acid-induced caspase-3 activity and apoptotic nuclear morphology
 
GCDCA (at 50 µM) induces caspase-3 activity in primary rat hepatocytes that peaks after 4 




Figure1: Pertussis toxin (PT) inhibits glycochenodeoxycholic acid (GCDCA)-induced caspase-3 activity and 
nuclear fragmentation. (A) Primary rat hepatocytes were treated for 4 hours with 50 µmol/L of GCDCA, 200 nmol/L 
of PT or a combination of both. PT was added 30 min prior to the addition of GCDCA. * P < 0.05 for GCDCA + PT 
vs. GCDCA alone. (B) Hepatocytes were treated with different concentrations of PT 30 min prior to the addition of 
50 µmol/L of GCDCA for 4 hours. (C) PT (200nmol/L) significantly inhibits GCDCA-induced caspase-3 activation. 
* P < 0.05 for GCDCA (50, 100, 200 µM) + PT vs GCDCA (50, 100, 200 µM) alone. (D) Acridine orange staining. 
Treatment with 50 µmol/L of GCDCA induces nuclear condensation and fragmentation which is blocked with 200 
nmol/L PT at 15 hours after the addition of GCDCA. (E) Sytox green staining. PT does not induce necrosis in 
hepatocytes after 15 hours. Hepatocytes treated with 5 mmol/L H2 O2 were used as positive control.
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The effect of PT on GCDCA-induced caspase-3 activity in primary rat hepatocytes was 
investigated at this time point. Exposure of primary rat hepatocytes to PT (200 nmol/L) alone did 
not induce caspase-3 activation in hepatocytes (Figure1 A), but significantly inhibited GCDCA-
induced caspase-3 activity in a dose-dependent manner, with maximum inhibition observed at 
200 nmol/L PT (-60%, P<0.05; Figure1 A and B). In all subsequent experiments a concentration 
of 200 nmol/L PT was used. PT attenuated the GCDCA-induced caspase-3 activity at different 
apoptotic concentrations of GCDCA (50-200 µM; Figure1 C). At higher GCDCA concentrations 
the primary mode of cell death shifts to necrosis [18]. PT may delay, rather than prevent GCDCA-
induced apoptosis in rat hepatocytes. To establish whether PT prevents, as opposed to delaying 
apoptosis, GCDCA-treated hepatocytes were stained with acridine orange after 6 and 15 hours 
exposure with and without PT. Nuclear fragmentation and condensation, markers for end-stage 
apoptosis, were hardly detectable 6 hours after the addition of GCDCA, but clearly increased over 
time (shown for 15 hours exposure; Figure1D). The formation of fragmented and condensed nuclei 
was inhibited when GCDCA-exposed hepatocytes (both after 6 and 15 h) were co-treated with 
PT, comparable to control levels (Figure1D). Importantly, PT alone did not induce necrosis in 
hepatocytes, nor did it increase the number of necrotic cells after exposure to GCDCA (Figure1E). 
Time window of anti-apoptotic action of pertussis toxin
PT irreversibly inhibits Gαi-signaling. If Gαi function is required for bile acid-induced 
apoptosis, pre-incubation with PT alone should also lead to inhibition of GCDCA-induced 
apoptosis in hepatocytes. Hepatocytes were pre-incubated with PT for 15 hours, which results in 
complete ADP-ribosylation of Gαi proteins [19]. Medium was removed and cells were washed and 
then exposed to GCDCA in fresh medium with or without PT for 4 hours. Caspase-3 activity was 
inhibited in the presence of PT and the protective effect of PT persisted in hepatocytes exposed to 
GCDCA in fresh medium without PT (Figure2A). These data show that the anti-apoptotic effect 
of PT is sustained in hepatocytes, suggesting that the protective effect of PT is mediated via PT-
catalyzed irreversible ribosylation of the α-subunit preventing the G-proteins from interacting with 
GPCRs [11, 20]. Furthermore, addition of PT up to one hour after the start of the of GCDCA 
treatment still exerted maximum protection against GCDCA-induced apoptosis (Figure2B). No 
protective effect of PT was detected when PT was added at later time points (2-3 h after GCDCA 
treatment; Figure2B). These data indicate that the anti-apoptotic effect of PT is rapidly induced in 
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hepatocytes and suggest the involvement of Gαi protein signaling pathways in the protective action 
of PT against GCDCA-induced apoptosis [19].
A B
Figure2: The protective effect of pertussis toxin (PT) against glycochenodeoxycholic acid (GCDCA)-induced 
apoptosis is mediated through inhibition of Gαi –proteins. (A)Hepatocytes were pre-incubated with 200 nmol/L 
of  PT for 15 hours after which cells were washed and exposed to 50 µmol/L of GCDCA alone (+/- PT) or with 
simultaneous addition of PT (+/+ PT). * P < 0.05 for GCDCA + PT (+ / -) and GCDCA + PT (+ / +) vs. GCDCA 50 
µM. (B) hepatocytes were stimulated with 50 µmol/L GCDCA for 4 hours (GCDCA 50 µM). PT (200 nmol/L) was 
added 30 minutes prior to (-30 min), simultaneous with (0 min) or 30 minutes (+30 min), 1 hour (+1 hr), 2 hours 
(+2 hrs), 3 hours (+3hrs) after the addition of GCDCA.* P <0.05 for -30 min of PT, 0 min of PT, +30 min of PT, +1 
hr of PT vs GCDCA alone.
Anti-apoptotic effect of pertussis toxin is not dependent on the activation of ERK1/2, p38 MAP Kinase, 
PI3-kinase and protein kinase C 
To investigate whether specific protein kinase pathways are involved in the anti-apoptotic effects 
of PT, GCDCA-exposed rat hepatocytes were co-treated with inhibitors of MAPK, PI3K and PKC. 
These inhibitors alone do not induce caspase-3 activity in rat hepatocytes (data not shown) [16]. 
The protective effect of PT against GCDCA-induced apoptosis was not abolished by inhibition of 
ERK1/2, p38 MAP kinases, PI3 kinase and PKC pathways (Figure3). This suggests that the anti-
apoptotic effect of PT is independent of the activation of these cell survival signaling kinases or that 
parallel pathways contribute to the protective effect and that inhibition of only one pathway does 
not result in increased apoptotic cell death.
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Figure3: The protective effect of pertussis toxin (PT) against glycochenodeoxycholic acid (GCDCA)-induced 
apoptosis is not dependent on the activation of p38 MAP kinase, ERK1/2 MAPK, PI3K pathway and PKC 
pathway. Caspase-3 activity in rat hepatocytes treated with 50 µmol/L of GCDCA in the presence and absence of 200 
nmol/L PT and with or without the inhibitors of ERK1/2- MAPK (10 µmol/L of U0126; U0), p38 MAPK (10 µmol/L 
of SB 203580; SB), PI3K (50 µmol/L of LY 294002; LY), PKC inhibitors (1 µmol/L  of  calphostin-C, 1 µmol/L of 
BSM-I).
Pertussis toxin protects hepatocytes against cytokine-induced caspase-3 activation and apoptotic nuclear 
morphology 
We also analyzed the effect of PT on cytokine-induced apoptosis in hepatocytes. TNFα, in 
combination with ActD, induces caspase-3 activation in hepatocytes that peaks around 16 hours 
[21]. PT significantly reduced TNFα/ActD-induced caspase-3 activity in rat hepatocytes (-60%, 
P<0.05; Figure4A). 
A B
Figure4: Pertussis toxin (PT) inhibits tumor necrosis factor-α/actinomycin-D (TNFα/ActD)-induced caspase-3 
activity and nuclear fragmentation. (A) Primary rat hepatocytes were treated for 16 hours with 20 ng/ml of TNFα in 
the presence of 200 ng/ml of ActD. 200 nmol/L of PT was added 30 min prior to the addition of TNFα/ActD. * P < 
0.05 for TNFα/ActD + PT vs. TNFα/ActD alone. (B) Acridine orange staining. Treatment with TNFα/ActD induces 
nuclear condensation and fragmentation which is blocked with 200 nmol/L PT.
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Acridine orange staining confirmed that TNFα/ActD-induced activation of caspase-3 resulted 
in the formation of fragmented and condensed nuclei, markers of end-stage apoptosis, after 16 
hours (Figure4B). Importantly, theses markers were absent when TNFα/ActD-exposed hepatocytes 
were co-treated with PT, confirming that apoptosis was strongly inhibited in the presence of PT 
(Figure4B). Our data show that the PT-sensitive α-subunit of G-proteins is also a key player in 
TNFα-induced apoptotic signal transduction in primary rat hepatocytes. 
Pertussis toxin does not inhibit apoptosis in HepG2-rNtcp cells
To investigate whether PT has the same anti-apoptotic effect in a human hepatocellular 
carcinoma cell line as it has in primary rat hepatocytes, we investigated the effect of PT in HepG2-
rNtcp cells. HepG2-rNtcp cells were pre-treated with PT for 30 minutes, followed by  exposure to 
GCDCA for 4 hours or TNFα/ActD for 16 hours. PT did not induce caspase-3 activity in HepG2-
rNtcp nor did it inhibit GCDCA-induced caspase-3 activation in these cells (Figure5A). Similarly, 
PT did not reduce the TNFα/ActD-induced caspase-3 activity in these cells (Figure5B). These data 
suggest that the PT-sensitive Gα-protein is specifically involved in the apoptotic signaling pathways 
in primary hepatocytes and not in hepatocellular carcinoma cells. 
A B
Figure5: Pertussis toxin (PT) does not inhibit apoptosis in HepG2-rNtcp cells. (A) Caspase-3 activity in HepG2-
rNtcp cells treated with 200 µmol/L of GCDCA in the presence and absence of 200 nmol/L PT. (B) HepG2-rNtcp 
cells were treated for 16 hours with 20 ng/ml of TNFα in the presence of 200 ng/ml of ActD. 200 nmol/L of PT was 
added 30 min prior to the addition of TNFα/ActD.
Discussion
In this study, we report that PT, an inhibitor of Gα-proteins, protects primary rat hepatocytes 
against bile acid- and cytokine-induced apoptosis. These effects are specific for primary rat 
hepatocytes and are not observed in the human hepatocellular carcinoma cell line HepG2-rNtcp. 
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We demonstrate that the protective effect of PT is rapidly induced in hepatocytes and is sustained 
in rat hepatocytes, although the protective action of PT appears to be independent of a single 
protein kinase (-signaling pathway). We propose that the PT-sensitive α-subunit of G-proteins is a 
key player in apoptotic signal transduction in rat hepatocytes.
 Among the PT-sensitive G-proteins, the Gi family is the largest family with wide expression 
in the different cells and Gβγ signaling is usually associated with the Gi family [8, 22]. Other 
PT-sensitive G-proteins have a more restricted distribution in neuroendocrine, visual and 
lingual tissues [8]. Regulation of gluconeogenesis by bile acids and regulation of lipoapoptosis 
by lysophosphatidilcholine has previously been shown to be mediated via GαiPCR-dependent 
mechanisms in hepatocytes [12, 14]. Our data suggest that PT-sensitive GPCRs (likely GαiPCRs) 
are involved in bile acid- and cytokine-induced apoptotic signal transduction in primary rat 
hepatocytes as well. Although the involvement of GαiPCRs in lipoapoptosis has been reported 
before [14], our data suggest that lipid mediators are not the only death effectors that use GαiPCRs 
dependent signaling pathways in hepatocytes. 
The specific effect of PT (i.e. catalyzing ribosylation) on the α-subunit of Gi-proteins can explain 
the rapidly induced and sustained (protective) effect of PT in our experiments. ADP-ribosylated 
Gαi-proteins are in an “off “state and cannot transduce GPCR-induced signals [11, 23]. Therefore 
the receptors that are coupled to these G-proteins are not able to induce signaling pathways upon 
activation by agonists. 
MAP kinase-, PI3 kinase- and PKC-signaling pathways play important roles in regulating 
hepatocyte death and survival in response to stress inducers [24-27]. In addition, cross-talk between 
GPCRs and these signaling pathways is responsible for cellular responses, such as cell proliferation, 
survival, migration and differentiation [28]. Interestingly, our findings indicate that the protective 
effect of the pertussis toxin against GCDCA-induced apoptosis is not grossly dependent on one of 
these signaling pathways and may actually be completely independent of these signaling cascades. 
This finding is remarkable because it has been reported that conjugated bile acids such as GCDCA 
induce phosphorylation of ERK1/2 and PI3K/Akt pathways in a PT-sensitive manner in primary 
rat hepatocytes [13]. Thus, one may assume that co-treatment with PT hypersensitizes hepatocytes 
to GCDCA-induced apoptosis via inhibiting cell survival pathways (e.g., ERK and PI3K/Akt). 
However, our findings demonstrate the opposite. It is accepted that PT is a general inhibitor for Gαi-
proteins and inhibits several GαiPCRs signal transduction pathways [8]. Therefore, it is likely that 
despite the inhibitory effect of PT on GCDCA-induced ERK1/2 and PI3K/Akt phosphorylation, 
the overall effect of PT in GCDCA-treated hepatocytes favors cell survival.
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TNFα/ActD induces apoptosis in hepatocytes via the activation of death receptor signaling 
cascade (extrinsic pathway), whereas GCDCA induces apoptosis in hepatocytes via the activation 
of the mitochondria-dependent apoptotic cascade (intrinsic pathway) [21, 29]. However, there is 
cross-talk between the bile acid-induced and cytokine-induced signaling cascades in hepatocytes 
[30, 31]. Ligand-independent transactivation of tyrosine kinase receptors, such as EGFR, is one 
of the crucial steps in the cross-talk between the intrinsic and the extrinsic apoptotic pathways in 
rat hepatocytes [31]. Tyrosine kinase receptor transactivation has been associated with GPCRs 
(reviewed in [32]). Given the involvement of EGFR transactivation in rat hepatocyte apoptosis 
and the anti-apoptotic effect of PT in rat hepatocytes (our data), we suggest that there is cross-talk 
between PT-sensitive GPCR/Gαi and the EGFR, which leads to apoptosis. Indeed, it has been 
observed that PT pretreatment of hepatocytes inhibited taurodeoxycholic acid (TDCA)-induced 
activation of the EGFR [13]. It is also reported that PT-sensitive Gi proteins are uniquely involved 
in the signal transduction pathway mediating EGF-induced activation of phospholipase C-gamma 
(PLCγ) and Ca2+ mobilization (via tyrosine phosphorylation of EGFR) in rat hepatocytes, but 
not in a rat liver cell line (WB) [33]. Whether GCDCA-induced activation of EGFR in primary 
hepatocytes is also PT-sensitive remains to be determined.
PT has no effect on apoptotic signaling pathways induced by GCDCA and TNFa/ActD in 
HepG2-rNtcp cells. This could be related to differences between (transformed) HepG2 cells and 
primary hepatocytes with regard to gene expression patterns, signaling cascades, GPCRs expression 
patterns and/or the ability of Gαi proteins to interact with the effector receptors such as EGFR [34, 
35]. Indeed, it has been shown that Gαi proteins are unable to produce a stable complex with the 
EGFR or other EGFR-induced signaling protein kinases (such as PLCγ) in the rat epithelial liver 
cell line, WB [33].
It is known that liver injury is often accompanied by apoptotic hepatocyte cell death [1]. High 
levels of bile acids, cytokines, reactive oxygen species, drugs and toxins can induce hepatocyte 
apoptosis. In the liver, massive hepatocyte apoptosis results in acute liver failure, whereas persistent 
hepatocyte apoptosis and necrosis is often associated with activation of hepatic stellate cells and 
fibrogenesis, chronic liver dysfunction and end-stage liver disease [1, 3]. Ideally, the most direct 
therapeutic strategy is to eliminate the cause of the liver injury. However, effective treatments do 
not exist for many liver diseases, including primary sclerosing cholangitis, NASH, alcohol-mediated 
hepatitis, viral hepatitis unresponsive to antiviral therapies and acute liver failure. Anti-apoptotic 
interventions are among the most promising therapeutic strategies for these diseases as they may 
reduce the apoptosis induced-inflammation and fibrogenesis [1, 36, 37]. GPCRs, are suggested as 
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novel targets for drug innovation, as they have pivotal roles in many physiologic functions (e.g., 
cell proliferation, angiogenesis, survival) and in multiple diseases including the development of 
cancer and  cancer metastasis. Excellent therapeutic benefits have been observed with some GPCR-
based drugs in clinical trials: e.g., the endothelin A receptor antagonists ZD4054 and atrasentan 
show good antitumor efficacy for ovarian and prostate cancer [5, 6, 38, 39]. GPCRs (e.g., orexin 
receptor, GPCR78 and LPA receptor) are also involved in the regulation of apoptosis in cancer cells 
via interaction with different intracellular regulators of apoptosis such as MAPK-, NF-κB- and p53-
associated pathways (reviewed in [6]). The participation of GPCR/Gαi in hepatocyte apoptosis 
suggests new targets for drug innovation for (chronic) liver diseases and liver cancer treatment 
in the future. E.g., activating death receptor-mediated apoptosis in cancer cells by death ligands 
(such as TRAIL, FasL and TNFα) is suggested as an effective therapeutic strategy in the treatment 
of hepatocellular carcinoma [40]; however, this strategy may lead to the induction of apoptosis 
in adjacent normal hepatocytes and loss of functional tissue. In this situation, an adjuvant anti-
apoptotic therapy that will inhibit cell death in normal hepatocytes but has no effect on cancer cells 
may prevent excessive liver damage. Our data suggest that GPCR/Gαi-based therapeutic strategies 
may serve as the anti-apoptotic adjuvant therapy, protecting normal tissue against inflammation, 
bile acid and/or drug-induced cell death.
 In summary, our data indicate that GPCRs/Gαi participates in several apoptotic signaling 
pathways in hepatocytes, but not in human hepatocellular carcinoma cells, and that inhibiting the 
αi subunit of G-proteins is a very effective anti-apoptotic strategy in vitro. The participation of 
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Background and Aim: Sphingosine kinases (SphKs) and their product sphingosine-1-phosphate 
(S1P) have been reported to regulate apoptosis and survival of liver cells. Cholestatic liver diseases 
are characterized by cytotoxic levels of bile salts inducing liver injury. It is unknown whether SphKs 
and/or S1P play a role in this pathogenic process. Here, we investigated the putative involvement 
of SphK1 and S1P in bile salt-induced cell death in hepatocytes. 
Methods: Primary rat hepatocytes were exposed to glycochenodeoxycholic acid (GCDCA) to 
induce apoptosis. GCDCA-exposed hepatocytes were co-treated with S1P, the SphK1 inhibitor 
Ski-II and/or specific antagonists of S1P receptors (S1PR1 and S1PR2). Apoptosis (by caspase-3 
assay and Acridine orange staining) and necrosis (by Sytox green staining) were quantified. 
Results: Ski-II significantly reduced GCDCA-induced apoptosis in hepatocytes (-70%, p < 
0.05) without inducing necrosis. GCDCA induced Ca2+ oscillations in hepatocytes and co-
treatment with the Ca2+ chelator BAPTA repressed GCDCA-induced apoptosis.  Ski-II inhibited 
the GCDCA-induced intracellular [Ca2+] oscillations. Transcripts of all five S1P receptors were 
detected in hepatocytes, of which S1PR1 and S1PR2 appear most dominant. Inhibition of S1PR1, 
but not S1PR2, reduced GCDCA-induced apoptosis by 20%. Exogenous S1P also significantly 
reduced GCDCA-induced apoptosis (-50%, p < 0.05), however, in contrast to the GCDCA-
induced (intracellular) SphK1 pathway, this was dependent on S1PR2 and not S1PR1. 
Conclusion:  Our results indicate that SphK1 plays a pivotal role in mediating bile salt-induced 
apoptosis in hepatocytes in part by interfering with intracellular [Ca2+] signaling and activation of 
S1PR1. Thus, inhibition of SphK1 may be an attractive therapeutic strategy to prevent hepatocyte 




Sphingosine kinases (SphK1 and SphK2) are a distinct class of lipid kinases that are rapidly 
activated by a variety of extracellular and/or intracellular stimuli and are implicated in modulating 
cell survival and apoptosis [1]. Additionally, activation of SphKs results in activation of inflammatory 
processes, including generation of inflammatory cytokines and reactive oxygen species [2-4]. 
SphKs catalyze phosphorylation of sphingosine to generate sphingosine 1-phosphate (S1P) [5, 6]. 
Interestingly, S1P has been reported to trigger both survival and apoptotic signals in different cell 
types [5, 7-13]. S1P acts as a first messenger through the G protein coupled receptors (GPCRs), 
termed S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5, which are differentially expressed in different 
tissues. The cell type-specific expression of S1P receptors (S1PRs), as well as their differential coupling 
to different G-proteins, provides a clue to the different functions of S1P [13]. Additionally, S1P 
can act as a second messenger in various cell types by activating calcium channels and increasing 
intracellular [Ca2+], thereby regulating cell proliferation, growth, migration and apoptosis [13, 14]. 
In chronic (cholestatic) liver diseases, the liver is exposed to increased levels of bile salts, cytokines 
and reactive oxygen species, all of which independently can lead to loss of functional liver mass due 
to hepatocyte cell death. Concomitantly, hepatic stellate cells become activated, start proliferating 
and produce excessive amounts of extracellular matrix proteins leading to liver fibrosis, which may 
progress to end-stage liver disease [15]. Hence, identifying the mechanisms of hepatocyte injury is 
crucial for developing new therapeutic strategies to prevent hepatocyte apoptosis. We have previously 
shown that the sodium-taurocholate cotransporting polypeptide (NTCP) is crucial for conjugated 
bile salt-induced hepatocyte apoptosis [16], suggesting that bile salt-induced intracellular signaling 
pathways play important roles in modulating hepatocyte apoptosis. Additionally, it has been shown 
that bile salt-induced apoptosis is a mitochondria-dependent process which coincides with increased 
intracellular [Ca2+] levels [17]. Interestingly, it has been suggested that SphK2 inhibition improves 
mitochondrial function and hepatocyte survival after hepatic ischemia-reperfusion [18]. However, 
the role played by SphK1 in hepatocyte apoptosis is currently unclear. In the present study we have 
investigated the role played by SphK1 in two models of bile salt- and cytokine-induced apoptosis 
in rat hepatocytes. We demonstrate that SphK1 plays a pivotal role in mediating bile salt-induced 
apoptosis in hepatocytes, but this kinase has no effect in cytokine-induced apoptosis. Additionally, 





Specified pathogen-free male Wistar rats (220-250 g) were purchased from Charles River 
Laboratories Inc (Wilmington, MA, USA). Animals were kept under standard laboratory 
conditions with free access to standard laboratory chow and water. All experiments were performed 
in accordance with the guidelines of the local Committee for Care and Use of laboratory animals.
Experimental design
 
Hepatocytes were isolated and cultured in mutiwell plates (Greiner bio-one) in William’s E 
medium in a humidified incubator at 37 ºC and 5% CO2 as described before [16]. Experiments 
were started after the attachment period of 4 hours. In order to induce apoptosis, monolayers of 
cultured primary hepatocytes were exposed to 50 µM GCDCA (Sigma-Aldrich, St Louis, MO, 
USA) for 4 hours or 20 ng/ml recombinant murine TNFα (R&D Systems, Abingdon, U K) 
for 16 hours. Where indicated, hepatocytes were treated with 10 µmol/L S1P (Sigma-Aldrich) 
prior to the exposure to the apoptotic stimulus. The following specific inhibitors were used: Ski II 
(Tocris Biosciences, Bristol, UK) inhibitor of SphK1 (1-10 µM), VPC23019 (Tocris Biosciences) 
antagonist of S1PR1 (5 or 10 µM), JTE-013 (Tocris Biosciences) antagonist of S1PR2 (5 or 10 µM), 
U0126 (Promega, Madison, USA) inhibitor of ERK1/2 (10 µM), SB 203580 (VWR, Amsterdam, 
the Netherlands) inhibitor of p38 MAPK (10µM), LY 294002 (VWR) inhibitor of PI3 kinase (50 
µM), Calphostin-C and Bisindolylmaleimide I (BSM-I) (VWR) inhibitors of protein kinase-C (1 
µM), actinomycin-D (Roche Diagnostics, Almere, the Netherlands) transcriptional inhibitor (200 
ng/ml). All inhibitors and receptor antagonists were added to the cultured hepatocytes 30 minutes 
prior to the apoptotic stimuli unless stated otherwise. The intracellular [Ca2+] chelator, BAPTA 
(25 µM, Sigma-Aldrich), was added 30 minutes prior to GCDCA. Hepatocytes cultured in HBSS 
(containing [Ca2+]/ [Mg2+]) instead of William’s E medium were used as an internal control in these 
experiments. All experiments were performed in triplicate and each experiment was repeated at least 
three times using hepatocytes from different rats. Cells were harvested at the indicated time points 




Caspase-3 activity was measured as described previously [16]. The arbitrary fluorescence unit 
(AFU) was corrected for the amount of protein. Protein concentration was determined using a 
commercially available kit (Bio-Rad, Veenendaal, the Netherlands ).
Quantitative PCR
RNA isolation, reverse transcription and quantitative real-time PCR (qPCR) were performed as 
described previously [19] and mRNA expression levels were calculated relative to the housekeeping 
gene 18S. Primers and probes are listed in Table 1.
Determination of intracellular [Ca2+] changes in hepatocytes
Freshly isolated hepatocytes were loaded with the Ca2+-probe Fura2 (3 µM, Molecular Probes, 
US) and Ca2+ imaging experiments were performed one hour after plating as described previously 
[20].
Statistical analysis 
Results are presented as the mean of at least 3 independent experiments ± SD. Two way ANOVA 
was used to determine significance of differences between experimental groups. A p-value of less 
than 0.05 (P < 0.05) was considered statistically significant.
Results
Sphingosine kinase-1 inhibition protects hepatocytes against GCDCA-induced apoptosis, but has no 
effect on TNFα/ActD-induced apoptosis
GCDCA (at 50 µM) and TNFα/ActD induce caspase-3 activity in primary rat hepatocytes 
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that peaks after 4 h- and 16 h-exposure, respectively [16]. Therefore, the effect of Ski II, a selective 
inhibitor of SphK1 [21], on GCDCA- and TNFα/ActD-induced caspase-3 activity was investigated 
at these time points. Ski II significantly inhibited the GCDCA-induced caspase-3 activity up to 70% 
(p<0.05), in a concentration-dependent manner (Figure1A).  Exposure of primary rat hepatocytes 
to Ski II (1-10 µM) alone did not induce caspase-3 activity, nor did it reduce the caspase-3 activity 
in TNFα/ActD-treated rat hepatocytes (Figure1A and B). Since no toxic effects of Ski II were 
observed at the highest concentration used, a concentration of 10 µM was used for all subsequent 
experiments. These data show that inhibition of SphK1 specifically protects primary rat hepatocytes 
against GCDCA-induced apoptosis indicating that SphK1 activity is pro-apoptotic in these cells.
A B
Figure1: Sphingosine kinase-1 (SphK1) inhibitor (Ski II) inhibits glycochenodeoxycholic acid (GCDCA)-
induced apoptosis in rat hepatocytes but does not inhibit tumor necrosis factor α/Actinomycin-D (TNFα/
ActD)-induced apoptosis. (A) Primary rat hepatocytes were treated for 4 hours with 50 µM of GCDCA, 1-10 µMof 
Ski II or a combination of both. Ski II was added 30 min prior to the addition of GCDCA. * P < 0.05 for GCDCA + 
Ski II vs GCDCA alone. (B) Hepatocytes were treated for 16 hours with TNFα (20 ng/ml)/ActD (200 ng/ml), 1-10 
µM of Ski II or a combination of both. Ski II was added 30 min prior to the addition of TNFα/ActD.
The anti-apoptotic effect of SphK1 inhibition  is independent of the activation of ERK1/2, p38 MAP 
Kinase, PI3-kinase, protein kinase C and gene transcription
To investigate whether specific kinase pathways are involved in the anti-apoptotic effects of 
Ski II, GCDCA-exposed rat hepatocytes were co-treated with inhibitors of MAPK, PI3K or PKC. 
These inhibitors alone did not induce caspase-3 activity in rat hepatocytes (data not shown) nor 
did they induce caspase-3 activity in hepatocytes co-treated with Ski II (Figure2). Importantly, 
the protective effect of Ski II against GCDCA-induced caspase-3 activation was not abolished by 
inhibition of ERK1/2, p38 MAPK, PI3K and PKC (Figure2), suggesting that the anti-apoptotic 
effect of Ski II is essentially independent of the activation of these kinase pathways. These inhibitors 
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at the concentrations tested here were effective in our positive control experiments (data not shown). 
In addition, we studied the role of gene transcription in the protective effect of Ski II against 
GCDCA-induced apoptosis. Actinomycin D (200 ng/ml) is an inhibitor of gene transcription 
and sensitizes hepatocytes to TNFα-induced apoptosis, but has no effect on GCDCA-induced 
caspase-3 activity in rat hepatocytes ([16] and our data). Also, ActD treatment did not abolish 
the protective effect of Ski II against GCDCA-induced caspase-3 activation (Fig. 2). This finding 
suggests that adaptive gene regulation is not required for the anti-apoptotic effect of Ski II against 
GCDCA-induced apoptosis.
Figure2: The protective effect of sphingosine kinase-1 inhibitor (Ski II) against glycochenodeoxycholic acid 
(GCDCA)-induced apoptosis is not dependent on the activation of p38 MAP kinase, ERK1/2 MAPK, PI3K 
pathway, PKC pathway and gene transcription. Caspase-3 activity in rat hepatocytes treated with 50 µM of GCDCA 
in the presence and absence of Ski II (10 µM) and with or without the inhibitors of ERK1/2- MAPK (10 µM of 
U0126; U0), p38 MAPK (10 µM of SB 203580; SB), PI3K (50 µM of LY 294002; LY), PKC inhibitors (1 µM of 
calphostin-C and BSM-I), transcription inhibitor (200 ng/ml of ActD). * P < 0.05 for GCDCA+ Ski II vs. GCDCA. 
The differences between gray and white bars are not significant.
GCDCA-induced apoptosis is dependent on mobilization of intracellular [Ca2+] and SphK1 inhibition 
blunts GCDCA-induced [Ca2+] oscillations in rat hepatocytes
It was previously shown that GCDCA-induced apoptosis coincides with intracellular [Ca2+] 
mobilization from the ER, caspase-12 activation and mitochondrial dysfunction resulting in leakage 
of cytochrome c [17], suggesting that intracellular [Ca2+] mobilization contributes to GCDCA-
induced apoptosis. We investigated the effect of BAPTA (25 µM), a chelator of intracellular [Ca2+] 
, on apoptosis in GCDCA-exposed hepatocytes. BAPTA did not increase caspase-3 activity in 
hepatocytes when added alone (Figure3A). Importantly, the GCDCA-induced caspase-3 activity 
was significantly reduced in BAPTA loaded hepatocytes (-50%, P<0.05), confirming that the 
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mobilization of intracellular [Ca2+] pools plays an important role in GCDCA-induced apoptotic 
signaling. The same results was obtained when hepatocytes cultured in HBSS (containing [Ca2+] 
/ [Mg2+]), serving as controls for experiments performed in Williams’ E medium, were analyzed 
(Figure3A). We investigated the pattern of intracellular [Ca2+] mobilization in GCDCA-exposed 




Figure3: Glycochenodeoxycholic acid (GCDCA)-induced apoptosis in rat hepatocytes is dependent on the 
intracellular [Ca2+] mobilizations and sphingosine kinase-1 (SphK1) inhibition blunts GCDCA-induced [Ca2+] 
oscillations in rat hepatocytes. (A) Primary rat hepatocytes were plated  in the William’s E medium (WE) or Hank’s 
buffered salt solution (HBSS) containing calcium and magnesium. Caspase-3 activity in rat hepatocytes treated with 
GCDCA (50µM) and with or without BAPTA (25 µM). Hepatocytes were loaded with BAPTA 30 minutes prior to 
the addition of GCDCA. * P < 0.05 for GCDCA+ BAPTA vs. GCDCA (in WE) and # P < 0.05 for GCDCA+ BAPTA 
vs. GCDCA (in HBSS). (B) The figure shows measurements of intracellular [Ca2+] oscillations in three representative 
hepatocytes loaded with Fura2-AM. Cells were incubated with 300 µM GCDCA and [Ca2+] oscillations were measured 
during 15-20 minutes. The traces shown are representative of those obtained in at least three independent experiments. 
(C) The figure shows measurements of intracellular [Ca2+] oscillation in two representative hepatocyte loaded with 
Fura2-AM. Cells were first perfused with 300 µM GCDCA (the left part of the graph in continuous line) and then with 
GCDCA (300 µM) + Ski II (10 µM), successively (the grey box). Subsequently cells were re-perfused with GCDCA 
(the right part of the graph). The traces shown are representative of those obtained in at least three independent 
experiments. [Ca2+]i oscillations were inhibited or less frequent in the presence of Ski II in 65% of hepatocytes that were 
individually imaged. ATP (10 µM) was used as an internal control.











[Ca2+]oscillations in rat hepatocytes starting about 2-8 minutes after the addition of GCDCA (Fig. 
3B). Incubation with 300 µM GCDCA did not induce necrosis in hepatocytes up to at least one 
hour (data not shown).We did not observe [Ca2+] oscillations with concentration below 300 µM 
GCDCA, likely due to the experimental limitations. Interestingly, the [Ca2+] oscillations induced 
by GCDCA were not coordinated in hepatocytes nor were they homogenously induced in all 
cells at the same time (Figure3B) unlike [Ca2+] oscillations induced by angiotensin II (see below). 
Importantly, these GCDCA-induced [Ca2+] oscillations were blunted in the presence of Ski II 
(10µM) in 65% of hepatocytes, which showed [Ca2+] oscillations induced by GCDCA (Figure3C), 
suggesting that GCDCA-induced [Ca2+] oscillations in these hepatocytes are mediated via S1P 
produced by SphK1. When added alone Ski II did not induce calcium oscillations (data not shown).
S1PR1-dependent signaling contributes to the pro-apoptotic effect of GCDCA while exogenous S1P 
protects hepatocytes against GCDCA-induced apoptosis via interaction with S1PR2
S1P acts as a first messenger via its receptors, S1PR1-5 [13]. We detected significant mRNA 
expression levels of all S1P receptors in rat hepatocytes (Figure4A). S1PR1 and S1PR2 were 
expressed more abundantly compared to the others, which is in accordance with a previous report 
[22]. We investigated the effect of inhibiting S1PR1 and S1PR2 on GCDCA-induced apoptosis 
using specific antagonists of S1PR1 (VPC23019, at 5 and 10µM) and S1PR2 (JTE-013, at 5 and 
10µM), respectively. None of these S1P receptor antagonists induced caspase-3 activation when 
added to hepatocytes alone (Figure4B). The apoptotic effect of GCDCA was reduced significantly 
(-20%, P<0.05) in the presence of S1PR1 antagonist, indicating that S1PR1-dependent signaling 
contributes to the pro-apoptotic effect of GCDCA (Figure4B). In contrast, the S1PR2 antagonist 
did not significantly inhibit GCDCA-induced caspase-3 activity, suggesting that GCDCA-induced 
apoptosis is not mediated via S1PR2-dependent signaling. In fact, hepatocytes may become even 
more sensitive to the toxic effect of GCDCA in the presence of the S1PR2 antagonist (Figure4B). 
Endogenous S1P can induce intracellular signaling pathways independent of S1P receptors 
and/or via interaction with S1P receptors while exogenous S1P interacts with S1P receptors. 
Therefore, different functions can be expected from endogenous S1P and exogenous S1P [8, 
13, 23]. Consequently, we also investigated the effect of exogenous S1P (10 µM) on GCDCA-
induced apoptosis in hepatocytes. The concentration of exogenous S1P (100 nM- 10 µM) that 
causes various responses in cells is comparable with the plasma and tissue concentrations of 
96
Chapter 6
S1P in vivo [23-26]. When added alone, S1P (10 µM) did not induce caspase-3 activation in 
rat hepatocytes, but significantly inhibited GCDCA-induced caspase-3 activity (-50%, P<0.05; 
Figure4C). Interestingly, the protective effect of exogenous S1P against GCDCA-induced apoptosis 
was reversed in hepatocytes co-treated with the S1PR2 antagonist (JTE-013, 10µM), but not in 




Figure4: Sphingosine-1 phosphate receptor 1 (S1PR1)-dependent signaling contributes to pro-apoptotic effect of 
GCDCA but not Sphingosine-1 phosphate receptor 2 (S1PR2), while exogenous sphingosine-1 phosphate (S1P) 
protects hepatocytes against GCDCA-induced apoptosis via interaction with S1PR2. (A) Expression pattern of S1P 
receptors (S1P-r 1-5) in rat hepatocytes. qPCR analysis for S1P receptors using cDNA of rat hepatocytes in primary 
cultures at 4 hours after plating. (B) Hepatocytes were treated with 5 and 10 µM of S1PR1 antagonist (VPC23019) 
or S1PR2 antagonist (JTE-013) 30 minutes prior to the addition of GCDCA (50 µM). * P < 0.05 for GCDCA+ 
VPC23019 vs. GCDCA. (C) Primary rat hepatocytes were treated for 4 hours with 50 µM of GCDCA with or without 
10 µM of S1P in the medium. S1PR2 antagonist (JTE-013, 10µM) and S1PR1 antagonist (VPC23019, 10µM) were 
added 30 min prior to the addition of S1P. * P < 0.05 for GCDCA+ S1P vs. GCDCA alone. (D) The upper figure 
shows measurements of intracellular [Ca2+] oscillation in three representative hepatocytes loaded with Fura2-AM. 
Cells were first incubated with 10 µM S1P and perfused with  S1P (10 µM) + GCDCA (300 µM), successively. 
Subsequently cells were washed and perfused with angiotensin II (AII, 10 nM), serving as a positive control. The traces 
shown are representative of those obtained in at least three independent experiments using  individual rat hepatocytes.
Exogenously added S1P (10 µM) did not induce [Ca2+] oscillations in rat hepatocytes (Figure4D) 
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and prevented . GCDCA-induced [Ca2+] oscillations. S1P did not lead to irreversible blockade of 
[Ca2+] oscillations as those could subsequently be induced by the positive control, angiotensin 
II (AII, 10 nM; Figure4D). These data indicate that exogenous S1P has anti-apoptotic effects in 
primary rat hepatocytes and acts via a S1PR2-dependent signaling pathway. 
Discussion
In the present study, we show that SphK1 inhibition reduces GCDCA-induced apoptosis 
in primary rat hepatocytes. We further demonstrate that the protective effect of Ski II occurs 
independently of various specific kinase pathways and of adaptive gene regulation. However, it is 
dependent on the mobilization of intracellular [Ca2+] and Ski II inhibits GCDCA-induced [Ca2+]
oscillations. We suggest that S1PR1-dependent signaling contributes to the pro-apoptotic effect of 
GCDCA. In contrast, exogenous S1P promotes cell survival against GCDCA-induced apoptosis 
via S1PR2-dependent signaling in rat hepatocytes (Figure5). 
SphKs and S1P have been implicated to play a role in apoptosis and survival of liver cells [1, 
8, 18]. SphK2 activation leads to the mitochondrial dysfunction and hepatocyte apoptosis after 
hepatic ischemia-reperfusion injury [18]. S1P may activate both apoptotic and survival pathways at 
the same time and the balance between the two pathways determines the end result. For instance, 
S1P is pro-apoptotic in human hepatic myofibroblasts acting via a receptor-independent pathway, 
while concomitant signaling via S1P receptors is anti-apoptotic [8]. The effect of SphK1 activation 
and S1P on hepatocyte apoptosis has not yet been elucidated. Hepatocyte apoptosis in response to 
elevated levels of toxic stimuli, such as bile salts, cytokines and reactive oxygen species, contributes 
to the pathogenesis of chronic liver diseases. Understanding the mechanisms of hepatocyte injury 
is therefore of great relevance for the development of therapeutic strategies to prevent hepatocyte 
apoptosis. Therefore, we studied the role played by SphK1 and S1P in in vitro models of bile salt 
(GCDCA)- and cytokine (TNFα)-induced hepatocyte apoptosis.
In our study, we have used Ski II to inhibit SphK1 signaling. Ski II is a selective inhibitor of 
SphK1 that does not act on the ATP-binding site of the enzyme and was shown to be highly specific 
for SphK1 up to 60 µM [21]. Using this strategy, our data indicate that GCDCA-induced apoptosis 
is in part dependent on SphK1 signaling in rat hepatocytes. In contrast to a previous report [10], we 
demonstrate that TNFα-induced apoptosis in rat hepatocytes is not SphK1-dependent. Osawa et al 
[10], analyzed the role of SphKs in human hepatoma cell lines and used non-selective (broad range) 
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inhibitors (DMS and DHS) of SphKs. In our study, we analyzed primary  rat hepatocytes and 
focused on the role of SphK1 by applying a highly selective inhibitor (Ski II). These experimental 
differences may explain the fact why we did not observe an effect of inhibition of SphK1 on TNFα-
induced apoptosis.
Figure5: Schematic drawing summerizing the proposed mechanisms for glychochenodeoxycholic acid (GCDCA)-
induced apoptosis in rat heptocytes involving sphingosine kinase-1 (SphK1), sphingosine-1 phosphate (S1P) 
and sphingosine-1 phosphate receptors (S1PR1 and S1PR2). ASMase: acidic sphingomyelinase, Ntcp: sodium-
taurocholate cotransporting polypeptide, Ski II: Sphk1 inhibitor. 
Endogenous S1P was shown to function as a powerful mediator of [Ca2+] release through a 
non-InsP3 receptor-mediated mechanism in the ER membrane [27, 28]. Furthermore, it has been 
demonstrated that UTP stimulates [Ca2+] mobilization in a SphK-dependent manner, which is not 
mimicked by exogenous S1P [29]. Altogether, these reports suggest that endogenous S1P generated 
by SphKs activation induces intracellular [Ca2+] mobilization. GCDCA-induced apoptosis in rat 
hepatocytes has been shown to coincide with elevated intracellular [Ca2+] levels [17]. Accordingly, 
we show that GCDCA-induced apoptosis is dependent on intracellular calcium mobilization, 
since the GCDCA-induced apoptosis was reduced in hepatocytes loaded with the [Ca2+] chelator 
BAPTA. In our experiments, the GCDCA-induced increase in [Ca2+] is coinciding with [Ca2+]
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oscillations. Remarkably, not all hepatocytes showed [Ca2+] oscillations in response to bile salts 
and the [Ca2+] oscillations were not coordinated in hepatocytes. It was previously shown that the 
lack of coordination of [Ca2+] oscillations in hepatocytes can result either from the absence of 
InsP3 production by bile salts or from the inhibitory effect of bile salts on the permeability of 
gap  junction channels [30, 31]. Although we did not specifically test these mechanisms, they may 
provide a clue to explain the lack of homogeneity and coordination of [Ca2+] oscillations induced 
by GCDCA in our experiments. Interestingly, we show that GCDCA induces [Ca2+] oscillations 
in a SphK1-dependent manner which, importantly, is not mimicked by exogenous S1P at the 
concentration that is anti-apoptotic in hepatocytes. It has previously been shown that exogenous 
S1P mobilizes intracellular [Ca2+] in rat hepatocytes [14, 32], but this did not present as [Ca2+]
oscillations. Therefore, we suggest that endogenous S1P generated by GCDCA-mediated pathways 
can act as a second messenger to induce [Ca2+] oscillations in rat hepatocytes. Inhibition of SphK1 
activation inhibits GCDCA-induced apoptosis as well as GCDCA-induced [Ca2+]oscillations.
[Ca2+]oscillations are implicated in the regulation of different cellular processes in hepatocytes 
including glucose metabolism and cell proliferation [33, 34]. [Ca2+] oscillations are reported to 
regulate transcriptional activity in cells [35, 36] although our data indicate that neither GCDCA-
induced apoptosis (18) nor the protective action of Ski II (present study) required adaptive gene 
regulation. Some cholestatic bile salts have been shown to increase intracellular [Ca2+] and induce 
[Ca2+] oscillations in rat hepatocytes [31, 37]. In the present study, we suggest that bile salt-induced 
[Ca2+] oscillations in rat hepatocytes promote apoptosis, however, the exact pathway of the [Ca2+]
oscillation-induced events in regulating apoptosis remains unclear. It is reported that TUDCA 
(a choleretic anti-apoptotic bile salt [16]) can also induce [Ca2+] oscillations in the H4-IIE cell 
line [38], however, this finding could not be confirmed in rat hepatocytes [31]. In addition, it is 
reported that TUDCA plays an important role in maintaining intracellular calcium homeostasis 
by reducing thapsigargin-induced release of [Ca2+] from ER stores, resulting in the maintenance of 
mitochondrial membrane potential and cell survival [39]. It is therefore highly likely that cholestatic 
bile salt-induced [Ca2+] oscillations in rat hepatocytes constitute a pro-apoptotic signal in these cells.
Activation of MAP-kinase signaling, PI3-Kinase signaling and PKC signaling pathways in 
hepatocytes play an important role in determining the balance between death and survival in 
response to stress [16, 40-43]. In addition, S1P and S1P receptors are reported to interact with 
these kinases [8, 10, 22, 44]. We hypothesized that the inhibition of these kinases would re-sensitize 
Ski II treated hepatocytes to GCDCA-induced apoptosis, but our data demonstrate that inhibition 
of ERK, PI3-kinase and/or PKC pathways are not involved in the protective effect of Ski II. 
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In the present study, we observe opposing functions for exogenous S1P versus endogenous S1P. 
Many reports indicate that S1P acts as a first messenger on cell surface S1P receptors in a paracrine 
and/or autocrine manner (reviewed in [45]). We suggest that in GCDCA-induced apoptosis, the 
main autocrine and/or paracrine role of S1P as a first messenger is to activate S1PR2-dependent 
survival signaling. It has been shown that in rat hepatocytes exogenous S1P can activate ERK1/2 
and Akt via interaction with S1PR2 [22]. Additionally, activation of ERK1/2 and Akt signaling 
pathways contribute to hepatocyte survival [16]. Activation of theses pathways could contribute 
to the protective effect of exogenous S1P against GCDCA-induced apoptosis. Interestingly, the 
GCDCA-induced activation of S1PR1-dependent signaling (likely by secreted endogenously 
generated S1P) is pro-apoptotic for rat hepatocytes, however, this pathway does not seem to 
play a major role in GCDCA-induced apoptosis as the antagonist of S1PR1 reduced GCDCA-
induced apoptosis only by 20%. Therefore, our evidence that GCDCA-induced apoptosis is a 
SphK1-dependent event indicates that the generated endogenous S1P acts as a second messenger to 
promote cell apoptosis in rat hepatocytes. Therefore, inhibiting SphK1 in hepatocytes could be an 
effective anti-apoptotic strategy in the treatment of cholestatic liver disease.
In summary, the results of this study demonstrate that GCDCA induces apoptosis in rat 
hepatocytes in a SphK1-dependent manner and suggest that endogenously generated S1P act as a 
second messenger to induce [Ca2+] oscillations and apoptosis in rat hepatocytes.
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Hepatocyte apoptosis is ubiquitous in liver diseases [1-6]. Although apoptosis is primarily a non-
inflammatory process responsible for the removal of excess or damaged cells, apoptosis in pathologic 
conditions is not controlled and can deteriorate organ function [7]. E.g. if apoptotic bodies are not 
eliminated, their membranes become permeable, leading to the release of cellular fragments into 
the extracellular space and triggering an inflammatory response. This process is called secondary 
necrosis [8]. In massive liver injury the ability of phagocytes to identify and clear apoptotic bodies 
is likely disturbed and an inflammatory response is observed despite an initial apoptotic stimulus 
in the liver [9, 10]. In addition, “diseased” hepatocytes can have adaptive alterations in their signal 
transduction pathways and organelle-regulated processes due to prolonged exposure to toxic stimuli 
such as excessive reactive oxygen species (ROS), toxic bile salts, free fatty acids and inflammatory 
cytokines. As a consequence they react differently than “normal” hepatocytes in response to these 
toxic stimuli (e.g., increased susceptibility of hepatocytes to primary necrosis instead of primary 
apoptosis, may lead to an exaggerated inflammatory response in the liver). Therefore, understanding 
the cellular processes and molecular signaling pathways regulating apoptosis and/or necrosis in 
(diseased) hepatocytes is essential to the development of new therapeutic strategies for (chronic) 
liver diseases.
Hepatocyte injury occurs upon exposure to toxic bile salts, inflammatory cytokines and 
increased levels of ROS. In this thesis, we have investigated the characteristic functions of steatotic 
and cholestatic hepatocytes using in vivo and in vitro models, respectively. Three models of 
hepatocyte cell death were studied: glycochenodeoxycholic acid (GCDCA)-induced cell death as a 
model for bile acid toxicity, tumor necrosis factor α (TNFα)/ actinomycin D (ActD, an inhibitor 
of transcription) as a model for cytokine-induced toxicity and menadione-induced cell death 
(menadione is a superoxide anion donor) as a model for oxidative stress-induced toxicity. These 
models are clinically relevant as these toxic stimuli are present at increased levels in most liver 
diseases.
Chapter 3 describes the susceptibility of the steatotic hepatocytes to apoptosis and necrosis. 
Hepatocyte necrosis is suggested to trigger an excessive inflammatory response in fatty livers, 
increasing the morbidity and mortality of NAFLD patients [11-14]. Previous studies in animal 
models of NAFLD suggested higher susceptibility of fatty heptocytes to endotoxin-induced injury 
and bile acid-induced necrosis [15, 16]. However, the underlying mechanisms of altered sensitivity 
of fatty hepatocytes are still a matter of debate. We used hepatocytes isolated from Zucker obese 
rats as a model of NAFLD [17]. Fatty hepatocytes showed clearly increased cellular necrosis shortly 
after the isolation, representing their vulnerability to necrosis in vivo as well. We hypothesized 
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that alterations in mitochondria-regulated processes play a role in this phenomenon in steatotic 
hepatocytes, as mitochondria play an important role in both apoptotic and necrotic cell death in 
hepatocytes [18-21]. An important step in the mitochondria-dependent cell death is mitochondrial 
permeability transition (mPT). Opening of the permeability transition pore (mPTP) in the inner 
membrane can trigger mPT.  Opening of the mPTP is thought to initiate necrosis rather than 
apoptosis [22, 23]. Cyclophilin D, ANT and VDAC are suggested to be related to the mPTP 
[23-27] and it is reported that cells overexpressing cyclophilin D are hypersensitive to necrotic 
cell death [28]. In accordance, our findings indicate that cyclophilin D is up-regulated in fatty 
hepatocytes. Although ANTs are thought to be non-essential components of the mPTP, they do 
have an important role in regulating the permeability transition by modulating the sensitivity 
of the mPTP to Ca2+ and ANT ligands [27]. Cyclophilin D is thought to facilitate a calcium-
triggered conformational change in the ANT converting it to an open pore [22]. Therefore, the up-
regulation of Ant-1 in fatty hepatocytes can also play a role in the increased susceptibility of steatotic 
hepatocytes to necrosis. We also observed an increase in mRNA expression levels of Vdac-1 and 
Vdac-3 in steatotic hepatocytes but we were not able to detect a difference in protein expression of 
Vdac-1 and Vdac-3 between lean and fatty hepatocytes. Whether the increase in mRNA expression 
level of Vdac-1 or Vdac-3 has a role in the susceptibility of fatty hepatocytes to necrosis and/or 
apoptosis remains to be established. Fatty hepatocytes were clearly resistant to bile acid-induced 
apoptosis, whereas they showed equal sensitivity to TNFα/ActD-induced apoptosis. Previously, 
we have shown that GCDCA induces apoptosis in primary rat hepatocytes in a mitochondria-
dependent manner while cytokine induces apoptosis in a death receptor-dependent manner [29, 
30], suggesting that alterations in mitochondria-mediated pathways are crucial in regulating bile 
salt-induced cell death in hepatocytes. Therefore, the up-regulation of mPTP proteins may also play 
role in the resistance of fatty hepatocytes to bile acid-induced apoptosis and their susceptibility to 
bile acid-induced necrosis.
Steatotic hepatocytes are exposed to increased levels of free fatty acids and oxidative stress, 
thus it is very likely that they adapt themselves to the environment. Mitochondria, as one of the 
main organelles for lipid metabolism in hepatocytes, are exposed to these stimuli and therefore, 
alterations in mitochondria-regulated pathways are not unexpected. In accordance, our findings 
confirm the presence of such alterations in steatotic hepatocytes, thereby predisposing them to 
necrosis. The consequence of susceptibility to necrosis rather than apoptosis is that hepatocytes 
in fatty livers are more prone to necrosis-induced inflammation. Once inflammation occurs, the 
prognosis of NAFLD patients is worse [11, 13]. Our study suggests potential targets for therapy to 
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prevent necrosis in fatty livers (e.g. inhibition of the mPTP and in particular the mPTP regulator, 
cyclophilin D), and thereby protect fatty livers against inflammation and exacerbation of liver 
damage.
Chapter 4 describes the protective effects of angiotensin II (AT-II) against bile salt-induced 
apoptosis in primary rat hepatocytes. AT-II antagonists (ACEi and/or ARB) are considered 
as therapeutics for fibrotic liver diseases as they prevent HSC activation and proliferation [31]. 
However, the effect of AT-II antagonist therapy on “diseased” (e.g. cholestatic) hepatocytes has 
not been studied. Importantly, ACEi- and ARB-induced hepatocellular injury and liver damage 
have been reported previously [32-37]. Several mechanisms have been suggested for ARB-induced 
hepatotoxicity and cholestasis such as metabolic idiosyncrasy and immune mechanisms. However, 
the hypothesis that angiotensin II has hepatoprotective effects and ARBs sensitize hepatocytes to 
toxic stimuli has not been investigated. In our study, we used several apoptotic stimuli (bile salts, 
oxidative stress and cytokine) that are present in chronic liver diseases, to investigate the effect 
of AT-II specifically on diseased hepatocytes. Our data strongly demonstrate that AT-II has AT-
1R-mediated hepatoprotective effects in hepatocytes which were exposed to cholestatic bile salts. 
These effects are prevented by several ARBs. Interestingly, AT-II protects hepatocytes against bile 
salt-induced apoptosis but not against TNFα- and menadione-induced apoptosis. This could be 
due to the induction of different signaling pathways in response to these apoptotic stimuli [29, 
38-40]. We have provided evidence that the protective effects of AT-II are mediated via combined 
activation of protein kinase signal transduction pathways including ERK, PI3K, p38 MAPK and 
PKC. We have shown previously that taurine-conjugated UDCA (TUDCA)-induced activation of 
ERK, PI3K and p38 MAPK protects primary rat hepatocytes against bile salt-induced apoptosis 
[41]. Thus, it is likely that AT-II mediated activation of these protein kinases leads to the survival 
of cholestatic hepatocytes. In addition, we observed that AT-II reduces bile salt-induced CHOP 
expression. CHOP is highly induced during ER stress, activating the ER stress-induced apoptotic 
pathways [42]. CHOP deficiency reduces cholestasis-induced hepatocyte apoptosis [43]. Activation 
of the ERK1/2, PI3K/Akt and PKC pathways were found to attenuate ER stress-induced apoptosis 
and reduce CHOP expression, leading to cell survival [44-47]. Interestingly, inhibition of the ER-
stress response by TUDCA is a hepatoprotective mechanism in liver disease [48]. Our data suggest 
that activation of these protein kinases in AT-II treated hepatocytes inhibits the ER stress response, 
leading to hepatocyte survival.
The hepatoprotective effect of AT-II against bile salt-induced apoptosis has great clinical 
relevance in AT-II antagonist therapy of patients with cholestatic liver fibrosis. Patients with chronic 
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cholestatic liver diseases (e.g., PSC, PBC) usually visit the clinicians when their disease is already 
advanced and the therapy has to start in already diseased livers containing cholestatic hepatocytes. 
Our data suggest that despite the beneficial effects of ARBs in the treatment of liver fibrosis, they 
may hypersensitize adjacent hepatocytes to several toxic bile salts such as taurolithocholic sulfate 
(TLCS) and GCDCA, leading to further loss of functional hepatocytes. Therefore, liver function 
should closely be observed during the AT-II antagonist therapy of cholestatic liver fibrosis, especially 
in the early stages of cholestatic liver disease. In addition, targeting AT-II antagonists specifically to 
hepatic stellate cells can be a good solution in order to protect functional hepatocytes during the 
treatment of liver fibrosis. Combined (taurine-conjugated) UDCA/ARBs therapy could serve as 
an alternative option to protect hepatocytes while treating liver fibrosis in cholestatic liver diseases, 
as UDCA has the same hepatoprotective effects as observed for AT-II in our study and UDCA is 
already used in clinic for patients with chronic cholestatic diseases. 
In chapter 5, the involvement of Gαi-protein coupled receptors (GPCR) in regulating 
hepatocyte apoptosis is investigated. In the liver, lysophosphatidylcholine acts via a GαiPCR-
dependent mechanism in regulating lipoapoptosis of hepatocytes [49]. Whether GαiPCR also 
plays a role in bile acid- or cytokine-induced apoptosis is not known. We report that pertussis 
toxin (PT), an inhibitor of Gαi-proteins, protects primary rat hepatocytes against apoptosis. The 
anti-apoptotic effect of PT is mediated via inhibition of GαiPCRs and is implicated in bile acid-
induced apoptosis as well as in cytokine-induced apoptosis in primary rat hepatocytes.  A crucial 
common step of both bile salt-induced apoptosis and cytokine-induced apoptosis in rat hepatocytes 
is ligand-independent transactivation of the epidermal growth factor receptor (EGFR, a tyrosine 
kinase receptor) [50-56]. Tyrosine kinase receptor transactivation has also been associated with 
GPCRs activation (reviewed in [57]). Given the anti-apoptotic effect of PT in rat hepatocytes in 
both models of apoptosis, we suggest that there is cross-talk between PT-sensitive GPCR/Gαi and 
the EGFR which leads to hepatocyte apoptosis. Indeed, it has been observed that PT pretreatment 
of hepatocytes inhibited taurodeoxycholic acid (TDCA)-induced activation of the EGFR [58]. It is 
also reported that PT-sensitive Gi proteins are uniquely involved in the signal transduction pathway 
mediating EGF-induced activation of phospholipase C-gamma (PLCγ) and Ca2+ mobilization 
(via tyrosine phosphorylation of the EGFR) in rat hepatocytes [59].Whether GCDCA-induced 
activation of the EGFR in primary hepatocytes is also PT-sensitive remains to be investigated. 
 Our data indicate that GPCRs/Gαi participate in several apoptotic signaling pathways in 
hepatocytes and that inhibiting the αi subunit of G-proteins is a very effective anti-apoptotic 
strategy in primary hepatocytes in vitro. Interestingly, we observed that PT has no protective effects 
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in bile salt- and cytokine-induced cell death in HepG2-rNtcp cells (hepatocellular carcinoma cell 
line).
The participation of GPCR/Gαi in hepatocyte apoptosis suggests new targets for drug innovation 
for (chronic) liver diseases and liver cancer treatment in future. E.g., activating death ligand-mediated 
apoptosis in cancer cells (e.g., TRAIL-, FasL-, TNF-mediated cell death) is suggested as an effective 
therapeutic strategy in the treatment of hepatocellular carcinoma [60]. However, this strategy may 
lead to the induction of apoptosis in adjacent hepatocytes and tissue damage. In this situation, an 
adjuvant anti-apoptotic therapy which will inhibit cell death in normal hepatocytes but has no 
effect on cancer cells may reduce the normal tissue damage. Our data suggest that GPCR/Gαi-
based therapeutic strategies may serve as the anti-apoptotic adjuvant therapy, protecting normal 
tissue.
Chapter 6 describes a novel bile salt-induced signaling pathway mediating hepatocyte apoptosis 
including sphingosine kinase-1, sphingosine-1 phosphate (S1P) and S1P receptors (S1PR1 and 
S1PR2).
It is known that sphingosine kinase (SphK) isoenzymes as well as endogenous and exogenous 
S1P have opposing functions in different cells and different organs [61-65]. Liver cells are also 
not excluded from this enigma. S1P is proapoptotic via a receptor-independent pathway and anti-
apoptotic via activation of S1P receptors in human hepatic myofibroblasts [66]. Sphk2 activation 
has been implicated in mitochondrial dysfunction and hepatocyte apoptosis after hepatic ischemia-
reperfusion injury [67]. However, the effect of SphK1 and S1P in bile acid-induced apoptosis is 
currently unclear. In this study, we report that Ski II (a selective inhibitor of SphK1) protects primary 
rat hepatocytes specifically against GCDCA-induced apoptosis. We suggest that GCDCA-induced 
SphK1 activation and subsequently generated endogenous S1P mediates apoptosis mainly via S1P 
acting as a second messenger in hepatocytes and partly via S1PR1-dependent signaling, whereas 
exogenous S1P protects hepatocytes against GCDCA-induced apoptosis via S1PR2-dependent 
signaling. We demonstrate that the protective effect of Ski II is independent of the activation of 
specific kinases and of gene transcription, but Ski II inhibits GCDCA-induced [Ca2+] oscillations 
in rat hepatocytes. We also demonstrate that GCDCA-induced caspase-3 activity is dependent on 
the mobilization of intracellular [Ca2+] in rat hepatocytes. 
In contrast to a previous report [68], we demonstrate that TNFα-induced apoptosis in rat 
hepatocytes is not SphK1 dependent. In this study [68], SphKs were inhibited by non-selective 
inhibitors (DMS and DHS), whereas we have used a selective inhibitor of SphK1 (Ski II). In 
addition, their experiments [68] were performed in human hepatoma cell lines, whereas we 
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used primary rat hepatocytes. The difference in our results could therefore be related to the use 
of different cell types and different inhibitors. Interestingly, we observed opposing functions for 
exogenous S1P versus endogenous S1P. Many reports indicate that S1P as a first messenger activates 
cell surface S1P receptors in a paracrine and/or autocrine manner (reviewed in [69]). We suggest 
that the main autocrine and/or paracrine role of S1P as a first messenger in our model is to activate 
S1PR2-dependent signaling and induce cell survival. It has been shown that S1P via interaction 
with S1PR2 induces phosphorylation of ERK1/2 and Akt in primary rat hepatocytes [70]. We 
have previously shown that activation of these pathways contributes to hepatocyte survival [41]. 
Therefore, these mechanisms could lend a clue to explain the protective effect of exogenous S1P 
against GCDCA-induced apoptosis. The activation of S1PR1-dependent signaling by autocrine 
S1P during GCDCA-exposure is then pro-apoptotic for rat hepatocytes. However, this pathway 
does not seem to contribute importantly to hepatocyte apoptosis as the antagonist of S1PR1 reduces 
GCDCA-induced apoptosis only by 20%. Therefore, the evidence that GCDCA-induced apoptosis 
is a SphK1-dependent event suggests that the endogenously generated S1P acts as a second messenger 
to promote cell apoptosis in rat hepatocytes. S1P is suggested to act as a second messenger to 
mobilize calcium from the ER [71, 72]. GCDCA-induced apoptosis in rat hepatocytes has been 
shown to be accompanied by increased intracellular [Ca2+] levels, likely from ER stores [73]. In 
our experiments, the GCDCA-induced increase in [Ca2+] in rat hepatocytes is observed as [Ca2+] 
oscillations. Interestingly, we show that GCDCA induces [Ca2+] oscillations in a SphK1-dependent 
manner which is not mimicked by exogenous S1P. In addition, we show that GCDCA-induced 
apoptosis is dependent on intracellular calcium mobilization, since GCDCA-induced apoptosis was 
reduced in hepatocytes loaded with BAPTA (a chelator of intracellur [Ca2+]). Therefore, we suggest 
that GCDCA-induced endogenous S1P can act as a second messenger to induce [Ca2+] oscillations 
in rat hepatocytes. Inhibition of the SphK1 activation inhibits GCDCA-induced apoptosis as 
well as GCDCA-induced [Ca2+] oscillations. In summary, our data suggest that GCDCA-induced 
SphK1 activation is among the initial events in the bile acid-induced apoptotic cascade. Therefore, 
inhibiting SphK1 in hepatocytes could be a very effective anti-apoptotic strategy in cholestatic liver 
diseases.
Conclusions and future perspectives
Knowledge about the cellular mechanisms regulating death and survival of liver cells is of clinical 
and scientific interest for developing new therapeutic strategies. This thesis describes that hepatocyte 
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death and survival is regulated at the cross-roads of intracellular organelles (e.g., mitochondria and 
endoplasmic reticulum), membrane-bound receptors (such as GPCRs and EGFR) and cell survival 
signaling pathways (such as ERK, PI3K and PKC) (Figure1). 
Figure1: Schematic picture summerizing the findings of this thesis. Hepatocyte death and survival is regulated at 
the cross-roads of intracellular organelles, membrane-bound receptors (such as GPCRs and EGFR) and cell survival 
signaling pathways (such as ERK, PI3K and PKC).
GαiPCRs are generally transducing apoptotic signals in hepatocytes. However, S1PR2 receptor 
(also a GαiPCR) can also transduce cell survival signals upon activation by extracellular ligands such 
as S1P. Small lipid molecules such as S1P act as signaling molecules in hepatocytes, thereby playing 
dual roles in determining the fate of hepatocytes (depending on their localization in hepatocytes). 
Cross-talk between GPCRs and tyrosine kinase receptors such as the EGFR is also of great interest, 
as this pathway appears to be a common mechanism for several toxic stimuli in liver diseases (such 
as bile salts and cytokines). Thus interference with this step may be a beneficial anti-apoptotic 
strategy in chronic liver diseases (such as cholestasis) with an inflammatory component. The fact 
that hepatocellular carcinoma cells may not share all the signaling components of apoptosis with 
primary hepatocytes suggests new targets for adjuvant anti-apoptotic therapies in tumor treatment 
to reduce normal tissue damage during anti-tumor therapy. Diseased hepatocytes, however, are 
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likely to have altered characteristics and /or responses when exposed to toxic stimuli. This has 
important consequences for drug innovation, since an anti-apoptotic strategy may not be as 
efficient in reducing liver inflammation as an anti-necrotic therapy in e.g. steatotic liver disease. 
Finally, targeting therapies to diseased cells (e.g. activated stellate cells and myofibroblasts in liver 
fibrosis) may show better outcome in chronic liver diseases and reduce toxic side-effects. E.g. ARBs, 
considered as therapy for liver fibrosis,  may have adverse effects in adjacent functional hepatocytes, 
thereby leading to further loss of liver function.  
Although we have used ‘diseased’ hepatocytes in some experiments (e.g. fatty hepatocytes), 
we did not use ‘real’ cholestatic hepatocytes. Cholestatic conditions were mimicked by exposing 
normal hepatocytes to cholestatic bile salts. Future studies should focus more on the use of ‘in vivo 
diseased’ hepatocytes to validate the findings obtained in this thesis. After all, when patients with 
liver disease visit clinicians their liver cells are not normal anymore but are ‘diseased’. Moreover, as 
all pathways and organelles are somehow interconnected and interact with each other in a reciprocal 
fashion future studies should also investigate the consequences of interrupting a single apoptotic 
pathway on another pathway, e.g. mitochondria-targeted therapy on ER-stress related phenomena 
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Chapter 8
Cholestatische en steatotische leverziekten hebben een significant aandeel in het totaal van 
leverziekten. Zowel cholestatische (zoals primaire biliaire cirrose: PBS, en primaire scleroserende 
cholangitis: PSC) en steatotische (zoals niet alcoholische steatohepatitis: NASH) leverziekten zijn 
geassocieerd met hoge morbiditeit en sterftecijfers. Bestaande therapieën zijn of niet erg effectief 
(bijv. steroïden of UDCA in het geval van PBC) of zijn geassocieerd met hevige moeilijkheden (bijv. 
levertransplantatie: orgaan donor te kort, orgaan afstoting, etc.).
Eén van de redenen voor het te kort aan effectieve therapie voor cholestatische en steatotische 
leverziekten is het ontbreken van gedetailleerde kennis van de pathogenetische mechanismen van 
deze ziekten. Beide ziektegroepen worden gekarakteriseerd door een geleidelijk en progressief verlies 
van gezonde hepatocyten wat leidt tot leverontsteking, fibrogene en eindstadium leverziekte. Verlies 
van cellen kan via apoptose of necrose (of een tussenvorm) gaan. Echter bestaat er een uitgebreide 
controverse tussen de basis kennis als de dominante vorm van celdood in deze ziekten. Echter, 
elke interventie of therapeutische strategie zou effectief moeten zijn in ‘zieke’ (d.w.z. steatotische 
of cholestatische) hepatocyten, want patiënten met chronische leverziekten komen vaak pas bij de 
dokter wanneer hun ziekte al vergevorderd is. Het doel van dit proefschrift is de mechanismen van 
celdood in (zieke) hepatocyten op te helderen en op die manier strategieën te ontwikkelen om de 
(zieke) hepatocyten te beschermen en leverschade te voorkomen.
In hoofdstuk 2 wordt de actuele kennis van celdood in hepatocyten met speciale nadruk op 
intracellulaire organel gemedieerde celdood en membraan gebonden receptoren die apoptose 
reguleren beoordeelt. 
Hoofdstuk 3 beschrijft de gevoeligheid van de steatotische hepatocyten op apoptose en necrose. 
Er wordt voorgesteld dat necrose van hepatocyten leidt tot een excessief inflammatoire respons in 
vette levers, verhoogde morbiditeit en sterftecijfers van NAFLD patiënten. Echter de onderliggende 
mechanismen van veranderde gevoeligheid van vette hepatocyten zijn nog steeds onderwerp van 
discussie. Hepatocyten geïsoleerd van dikke Zucker ratten zijn gebruikt als model voor NAFLD. 
Vette hepatocyten laten duidelijk verhoogde cellulaire necrose zien kort na de isolatie, wat 
representatief is voor hun gevoeligheid voor necrose in vivo. Onze hypothese is dat veranderingen 
in mitochondrieel gereguleerde processen een rol spelen in dit fenomeen in steatotische hepatocyten 
want mitochondria spelen een belangrijke rol in zowel apoptotische als necrotische celdood. Een 
belangrijke stap in de mitochondrieel afhankelijke celdood is de mitochondrial permeability 
transition pore (mPT). Het openen van de mitochondrial permeability transition pore (mPTP) 
in de binnenste membraan kan leiden tot mPT. Van het openen van de mPTP wordt gedacht dat 
het leidt tot necrose i.p.v. apoptose. Van Cyclophilin D, ANT en VDAC wordt gedacht dat ze 
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gerelateerd zijn aan de mPTP. Wij zagen een verhoging op mRNA niveau van Vdac-1 en Vdac-3 
in steatotische hepatocyten. Vette hepatocyten zijn duidelijk resistent tegen galzout geïnduceerde 
apoptose, maar tonen een gelijke gevoeligheid voor TNFα/ActD geïnduceerde apoptose. Onze 
therapie laat potentiele doelen zien voor therapie om necrose te voorkomen in vette levers (bijv. 
remmen van de mPTP en met name de mPTP regulator, cyclophilin D) en daarmee vette levers te 
beschermen tegen ontsteking en een toename van de leverschade.
Hoofdstuk 4 beschrijft het beschermende effect van angiotensine II (AT-II) tegen galzout 
geïnduceerde apoptose in primaire rat hepatocyten. AT-II antagonisten (ACEi en/of ARB) worden 
gezien als medicijnen voor fibrotische leverziekten want zij houden de activatie en proliferatie van 
HSC tegen. Hoewel het effect van AT-II antagonist therapie op ‘zieke’(cholestatische) hepatocyten 
nog niet bestudeerd is. In deze studie hebben we verschillende aopototische stimuli (galzouten, 
oxidatieve stress en cytokine) gebruikt die aanwezig zijn in chronische leverziekten om het effect 
van AT-II specifiek op zieke hepatocyten te onderzoeken. Onze data laat duidelijk zien dat AT-II een 
AT-1R gemedieerd beschermend effect heeft op hepatocyten die blootgesteld zijn aan cholestatische 
galzouten. Deze effecten worden voorkomen door verschillende ARBs. AT-II beschermt hepatocyten 
tegen galzout geïnduceerde apoptose maar niet tegen TNFα- en menadion geïnduceerde apoptose. 
Wij laten zien dat de beschermende affecten van AT-II gemedieerd zijn via gecombineerde activatie 
van proteïne kinase signaal transductie routes waaronder ERK, PI3K, p38 MAPK en PKC. 
Daarnaast zien we dat AT-II de galzout geïnduceerde CHOP expressie reduceert. CHOP is erg 
geïnduceerd tijdens ER stress, wat leidt tot activatie van de ER-stress geïnduceerde apoptotische 
routes. Een CHOP tekort reduceert cholestase geïnduceerde apoptose van de hepatocyten. Activatie 
van ERK1/2, PI3K/Akt en PKC routes blijkt de ER stress geïnduceerde apoptose te verzwakken 
en de CHOP expressie te reduceren wat leidt tot cel overleving. Onze data laat zien dat activatie 
van deze proteïne kinases in AT-II behandelde hepatocyten de ER stress response remmen wat 
leidt tot hepatocyt overleving. Het lever beschermende effect van AT-II tegen galzout geïnduceerde 
apoptose is van groot klinisch belang in AT-II antagonist therapie bij patiënten met cholestatische 
leverfibrose. Patiënten met chronische cholestatische leverziekten (bijv. PSC, PBC) bezoeken hun 
dokter normaal gesproken pas wanneer hun ziekte al vergevorderd is en de therapie moet dan starten 
in een lever die al ziek is en cholestatische hepatocyten bevat. Onze data laat zien dat ondanks de 
voordelige effecten van ARBs in de behandeling van leverfibrose ze de aangrenzende hepatocyten 
overgevoelig maken voor verscheidene toxische galzouten zoals taurolithochol sulfaat (TLCS) en 
GCDCA, wat leidt tot het verder verlies van functionele hepatocyten. Daarom moet de leverfunctie 
goed in de gaten worden gehouden tijdens de AT-II antagonist therapie van de cholestatische 
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leverfibrose, met name tijdens de eerste stadia van de cholestatische leverziekte. Daarnaast kan 
het richten van AT-II antogonisten specifiek tot hepatische stellaat cellen een goede oplossing zijn 
om functionele hepatocyten tijdens behandeling van leverfibrose te beschermen. Gecombineerde 
(taurine geconjugeerde) UDCA/ARBs therapie zou een goed alternatief kunnen zijn om hepatocyten 
te beschermen tijdens de behandeling van leverfibrose in cholestatische leverziekten want UDCA 
heeft hetzelfde lever beschermende effect als we zien bij AT-II in dit proefschrift en UDCA wordt 
al in de kliniek gebruikt bij patiënten met chronische cholestatische ziekten.
Hoofdstuk 5 beschrijft het beschermende effect van pertussis toxine (PT), de Gαi-proteïne 
remmer, tegen galzout en cytokine geïnduceerde apoptotische celdood. Een cruciale stap in zowel 
galzout geïnduceerde apoptose en cytokine geïnduceerde apoptose in rat hepatocyten is de ligand 
afhankelijke transactivatie van de epidermale groeifactor receptor (EGFR, een tyrosine kinase 
receptor). Vanwege het anti- apoptotische effect van PT in rat hepatocyten in beide modellen van 
apoptose denken wij dat er een interactie is tussen PT gevoelige GPCR/Gαi en de EGFR wat leidt 
tot apoptose in de hepatocyt. Onze data laat zien dat GPCRs/Gαi deelnemen in verschillende 
apoptotische signaal routes in hepatocyten en dat het remmen van de αi subeenheid van G-proteïne 
een zeer effectieve anti-apoptotische strategie is in primaire hepatocyten in vitro. We hebben gezien 
dat PT geen beschermende effecten in galzout en cytokine geïnduceerde celdood in HepG2.rNtcp 
cellen (hepatocellulaire carcinoma cellijn) heeft.
Het deelnemen van GPCR/Gαi in apoptose van hepatocyten geeft nieuwe ideeën voor 
medicijn ontwikkeling voor (chronische) leverziekten en lever kanker behandeling in de toekomst. 
Bijvoorbeeld de activering van dood ligand gemedieerde apoptose in kanker cellen (bijv. TRAIL, 
FasL, TNF gemedieerde celdood) kan een effectieve therapeutische strategie zijn in de behandeling 
van hepatocellulaire carcinoma. Hoewel deze strategie kan leiden tot de inductie van apoptose in 
aangrenzende hepatocyten en weefsel schade. In deze situatie, een aanvullende anti-apoptotische 
therapie welke celdood in normale hepatocyten remt maar geen effect heeft op kanker cellen zal 
de schade in normaal weefsel reduceren. Onze data laat zien dat de op GPCR/Gαi gebaseerde 
therapeutische strategieën kan dienen als een anti-apoptotisch aanvullende therapie, om normaal 
weefsel te beschermen.
Het begrijpen van galzout geïnduceerde signaal routes is belangrijk voor de ontwikkeling 
van nieuwe medicijnen voor cholestatische afwijkingen. Hoofdstuk 6 laat een nieuwe galzout 
geïnduceerde signaal route zien, die bestaat uit sphingosine kinase-1 (SphK1), sphingosine-1 
fosfaat (S1P, een intracellulair lipide molecuul die zich gedraagt als second messenger) en S1P 
receptoren in primaire hepatocyten. Het is bekend dat sphingosine kinase (SphK) iso-enzymen 
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maar ook endogeen en exogeen S1P tegengestelde functies in verschillende cellen en verschillende 
organen hebben. SphK2 activatie is betrokken bij mitochondreel disfunctioneren en apoptose van 
hepatocyten na hepatische ischemie reperfusie schade. Hoewel het effect van SphK1 en S1P in 
galzout geïnduceerde apoptose momenteel onduidelijk is. In deze studie laten we zien dat Ski-II 
(een selectieve remmer van SphK1) specifiek primaire rat hepatocyten beschermd tegen GCDCA 
geïnduceerde apoptose. Wij zeggen dat GCDCA geïnduceerde SphK1 activatie en de daarop 
volgend de endogene generatie van S1P gereguleerde apoptose voornamelijk via S1P als second 
messenger gaat in hepatocyten en gedeeltelijk via S1PR1 afhankelijke signalering, waar exogeen 
S1P hepatocyten beschermd tegen GCDCA geïnduceerd apoptose via S1PR2- afhankelijke 
signalering. Wij laten zien dat het beschermende effect van Ski-II onafhankelijk is van de activatie 
van specifieke kinases en van gen transcriptie maar Ski-II remt GCDCA geïnduceerde [CA2+] 
fluctuaties in rat hepatocyten. We laten ook zien dat GCDCA geïnduceerde caspase-3 activiteit 
afhankelijk is van mobilisatie van intracellulair [Ca2+] in rat hepatocyten. Samenvattend laat onze 
data zien dat GCDCA geïnduceerde SphK1 activatie één van de belangrijkste onderdelen is van de 
galzout geïnduceerde apoptotische cascade. Daarom kan het remmen van SphK1 in hepatocyten 
zeer effectief zijn als anti-apoptotische strategie in cholestatische leverziekten.
Conclusies en toekomst perspectieven
Kennis van de cellulaire mechanismen die het afsterven en overleving van levercellen reguleert is 
van klinisch en wetenschappelijk belang voor de ontwikkeling van nieuwe therapeutische strategieën. 
Dit proefschrift beschrijft dat hepatocyten celdood en overleving zijn gereguleerd door middel 
van intracellulaire organellen (zoals mitochondria en het endoplasmatisch reticulum), membraan 
gebonden receptoren (zoals GPCRs en EGFR) en cel overlevingsroutes (zoals ERK, PI3K en PKC). 
Het feit dat hepatocellulaire carcinoma cellen niet dezelfde signalerings onderdelen van apoptose 
delen met primaire hepatocyten laat nieuwe doelen zien voor aanvullende anti-apoptotische 
therapieën in tumor behandeling om schade aan normaal weefsel te voorkomen tijdens anti tumor 
therapie. Zieke hepatocyten daarentegen hebben veranderde karakteristieken en/of reacties wanneer 
ze aan toxische stimuli blootstaan. Dit heeft belangrijke consequenties voor medicijn ontwikkeling 
omdat een anti-apoptotische strategie niet zo efficiënt is in gereduceerde leverontsteking als een 
anti-necrotische therapie in bijvoorbeeld steatotische leverziekten. Tot slot, therapieën gericht 
tegen zieke cellen (bijv. geactiveerde stellaat cellen en myofibroblasten in leverfibrose) hebben een 
betere uitkomst in chronische leverziekten en reduceren toxische bijwerkingen. Bijvoorbeeld ARBs, 
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gezien als therapie voor leverfibrose, kunnen nadelige effecten hebben in aangrenzende functionele 
hepatocyten wat leidt tot een verder verlies van de lever functie.
Ondanks we ‘zieke’ hepatocyten hebben gebruikt in sommige experimenten (bijv. vetten 
hepatocyten) hebben we geen gebruik gemaakt van echte cholestatische hepatocyten. Cholestatische 
condities werden nagebootst door het blootstellen van normale hepatocyten aan cholestatische 
galzouten. Toekomstige studies zouden de nadruk meer moeten leggen op het gebruik van in vivo 
ziek gemaakte hepatocyten om de bevindingen van dit proefschrift te controleren. Daarnaast als 
alle routes en organellen met elkaar verbonden zijn en met elkaar communiceren in een wederzijdse 
manier dan moet toekomstig onderzoek ook de gevolgen van het onderbreken van één enkele 
apoptotische route op een andere route onderzoeken, bijvoorbeeld mitochondria gerichte therapie 
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